BioTOP-Report. Biotech and Pharma in Berlin-Brandenburg

BioTOP-Report 2014 Biotech and Pharma in Berlin-Brandenburg

BioTOP-Report 2014 Content Editorial The German Capital Region Biotechnology and Life Sciences are Ready for the Future 3 Biotechnology The Capital Region New Jobs and New Companies 4 Pharma Attractive Location 14 Glycoscience Glyco Research for Innovations in Health Industry 18 Bioelectronics The Joint Lab Bioelectronics A New Platform for the Integration of Microelectronics into Life Sciences 20 Business Location Excellent Services for Berlin-Brandenburg 24 Spotlight on European Business and Internationalization The Enterprise Europe Network Berlin-Brandenburg 26 Biotech Parks The BioCampus Network Berlin-Brandenburg 34 Addresses 39 Publisher: Berlin Partner für Wirtschaft und Technologie GmbH BioTOP Berlin-Brandenburg Fasanenstraße 85 10623 Berlin Germany Phone +49 30 318622 0 Fax +49 30 318622 22 biotop@biotop.de www.healthcapital.de Editor: Volker Erb Design & Production: webersupiran.berlin Translation: Kate Abbott Berlin Photos/Figures: BioTOP or authors and: Page 14 Paulus Rusyanto/dreamstime.com, Sean Pavone/dreamstime.com Page 21 Warenemy/dreamstime.com, Collpicto/dreamstime.com Page 27 adimas/fotolia (Profile Alacris), Noah Clayton/co.don (Profile co.don) Page 30 Werner Popp (Profile organobalance).

BioTOP-Report 2014 Editorial The German Capital Region Biotechnology and Life Sciences are Ready for the Future Berlin-Brandenburg is an extremely attractive location for research and its translation into industrial applications. The establishment of the Berlin Institute of Health, successful spin-offs and inward investment show that the German capital region provides top conditions for the healthcare industry. Berlin is the start-up capital of Germany! With its new Healthcare Industries master plan, the capital region is setting the course for the sector s development until 2018. Basic research, innovation, spin-offs and application in the future, these will remain the four pillars that determine the successful implementation of the cluster strategy in Berlin-Brandenburg. Biotechnology/pharmaceuticals, medical technology and the healthcare industries are the focal areas. In the coming years, biotechnology/pharmaceuticals development will feature: The creation of new translation platforms in basic research, clinical research and industrial biotechnology Max Planck and Fraunhofer Research, as well as the Helmholtz and Leibnitz Institutes, are drivers of technology transfer and pioneers of innovative technologies and products. Development of new growth fields in the life sciences with interdisciplinary technologies Cross innovation at the interface of microsystems technology, microelectronics, photonics and surface engineering and thin films open up completely new opportunities for analytics, automation and hardware development and along with this, for growth, value creation and cost reduction. Value chain expansion via inward investment and industrial location expansion With more than 200 biotechnology companies, over 30 research institutions and over 130 clinics and hospitals, Berlin-Brandenburg is already a European hot spot for the life sciences. Growth in expertise, players and investment will reinforce the capital region s leading position in the international markets. Concentration on therapy development through new system medicine strategies The Max Delbrück Center for Molecular Medicine and Charité Universitätsmedizin Berlin are the umbrella for the new flagship of German biomedicine. In diagnostics, focus on the development of companion diagnostics Laboratory medicine, applied research, SMEs and the pharmaceuticals industry are pooling their activities for therapy optimization in personalized medicine. This new edition of the BioTOP Report provides you with an exciting, informative overview of the development in the capital region s industries. With themes such as glyco-engineering technology and bioelectronics, it underscores internationally outstanding activities. We wish you reading pleasure and invite you to commit to Berlin-Brandenburg as a place to develop your business. Reach out and contact us! In regenerative medicine, concentration on the development of new cell therapies The Berlin-Brandenburg Center for Regenerative Therapies (BCRT), biotechnology SMEs and pharmaceuticals partners in the international Regenerative Medicine Coalition are part of a high-performance product development network. Focus on the sustainable use of biological resources for medical applications in industrial biotechnology The Leibniz Institute for Agricultural Engineering, university-related research and biotechnology SMEs are successfully implementing the federal government s bioeconomics strategy and contributing to the strength of the healthcare industries. Prof. Dr. Peter Seeberger Expert Circle Spokesman Biotech/Pharma Dr. Günter Peine Head of BioTOP Berlin-Brandenburg 3

BioTOP-Report Biotechnology Biotechnology The Capital Region New Jobs and New Companies The growth trend of recent years continues in 2013. Employee numbers have grown by 5.6 % (last year, 6.5 %). Currently, 232 companies employ 4,586 people. The constant momentum is accompanied by many newly founded businesses. kk According to the latest BioTOP survey, 232 biotechnology companies are active in the Berlin-Brandenburg region. This means the company base has expanded by a total of 10 companies against last year. kk A total of 14 companies have stopped doing business in the region, either shutting down completely or relocating. kk The addition of 24 companies more than compensated for this loss. Of the new companies, we count 6 additions due to inward investment and new registration and particularly notable 18 start-ups. kk The current base of 232 companies has created 352 new jobs. This translates into a growth rate of over 8 percent. kk After subtracting the 114 jobs lost due to business shut-downs, the sector in the region gained a total of 273 jobs, adding up to regional employment growth of 5.6 % in the sector. For many years, biotechnology region Berlin-Brandenburg has been on a steady growth course. One of the sector s leading regions in Germany and Europe, it hosted 18 start-ups last year alone a figure to note. This speaks volumes in favor of the location s general conditions and the commitment of the many players involved and their start-up-related activities. And above all, underscores the courage of the many company founders who are seeking their fortune in this highly sophisticated sector. Smaller companies dominate the region s business landscape: 139 companies in the sector have less than 10 employees. Only 13% of the total jobs are located in these companies, however. Over 53% of the sector s employees in the region work for the 19 companies with more than 50 employees. The majority of these companies (88%) focus on the areas of new therapeutic agents, diagnostic products and biopharmaceuticals services; followed by 19% in the agriculture/food sectors and 13% in the industrial biotechnology sector (multiple mentions). The start-ups still have little effect on the job market. At their launch, none of these companies had more than 10 employees. JANUARY 2013 Epigenomics AG hands in fourth module at FDA completes application for approval as planned +++ co.don AG applied for approval of joint cartilage product chondrosphere in the EU +++ Shire discovered the Munich-based RNA specialist Ethris for itself. In cooperation the two companies want to find therapies for rare diseases FEBRUARY 2013 Epigenomics receives notice about grant of priority review status and acceptance of the hand-in of the PMA application for Epi procolon from the FDA +++ Innovation forum Biopolymers and Bio-based Plastics in Schwarz heide MARCH 2013 BIOTECON Diagnostics GmbH extends its robot segment +++ Epigenomics AG collects 5,0 million Euros through capital increase +++ New research collective INNO-TRACE develops innovative contrast agents for tumour imaging APRIL 2013 Europe's largest clinical laboratory at Campus Virchow-Klinikum: Labor Berlin inaugurates new site MAY 2013 Bayer HealthCare presents new incubator model for biotech start-ups in Berlin JUNE 2013 Alacris Theranostics GmbH announces Illumina CSPro certificate for next generation sequencing +++ Humedics co-founder Martin Stockmann receives Von- Langenbeck Prize for development of LiMAx test JULY 13 Berlin-Brandenburg Healthcare Industries cluster HealthCapital launches new website: www.healthcapital.de +++ Caprotec expands alliance with Bayer +++ EZAG AG in participation via subsidiary OctreoPharm Sciences GmbH +++ caprotec bioanalytics GmbH and Bayer CropScience enter into second research collaboration +++ NOXXON Pharma completes patient recruitment for phase IIa study in diabetic nephropathy +++ Romer Labs and the Institute for Product Quality (ifp) launch new AgraQuant F.A.S.T. AUGUST 13 Bayer HealthCare concludes partnership and license agreement with Compugen Ltd. for the research, development and marketing of antibody-based drugs for cancer immunotherapy. +++ caprotec bioanalytics GmbH and Syngenta International AG announce research collaboration +++ Epigenomics AG agreement with YA Global Master SPV Ltd. brings funding of up to 5 million SEPTEMBER 13 Eckert & Ziegler BEBIG s.a. takes over prostate cancer implantation business of American company Biocompatibles Inc. for $5 million +++ Myelo Therapeutics GmbH successfully completes funding round for the development of adjuvant cancer therapy OCTOBER 13 Epigenomics and Polymedco sign commercialization agreement for Epi procolon for the North American market +++ Sugar is life: GlycoUniverse successfully launched in Campus Buch +++ Cell Medica, a leading company in the T-cell 4

BioTOPics 47 6. Juni 2014 (3:02) BioTOP-Report Biotechnology Dr. Matthias Schroff CEO MOLOGEN AG Key milestones achieved MOLOGEN completed a successful fiscal year 2013 with three different product candidates in clinical development for the first time. The final evaluations for the completed clinical trials of MGN1703 and MGN1601 provided very positive data, and with MGN1404 (a product that combats malignant melanoma), the company launched the clinical development phase of another product candidate within the framework of a partnership, contributing to an expansion of its pipeline. For its most advanced product candidate, the cancer immunotherapy MGN1703, MOLOGEN was also able to present very positive clinical data from the final evaluation of a phase II trial in colorectal cancer (IMPACT study) in 2013. For the most part, the preparations for a phase III pivotal study in this indication were completed in the course of the last fiscal year. Glycotope specializes in the glycosylation of proteins. Glycotope has a broad portfolio of drugs in clinical development, including the new cancer drugs, PankoMab-GEX and CetuGEX, both in phase IIb trials. PankoMab-GEX is the first fully glycosylated and glyco-optimized human antibody for a novel tumor-specific carbohydrate-protein mixed epitope (TA-MUC1) abundantly present in a larger set of tumor indications, metastases and cancer We are well aware that our company s success is also due to the conditions that Berlin and the capital region offer. Whether research collaboration (FU Berlin) or clinical studies with Charité Universitätsmedizin and its departments we benefit from the close scientific network. The availability of qualified personell is also a key advantage, which surely ties into the high quality of life in Berlin. Berlin is a city for conferences and conventions and many of our sector associations have their headquarters here. This is another reason why Berlin is an excellent location for medical biotechnology. As a research company, we appreciate the fact that Berlin is one of the world's leading regions and innovative locations in the field of life sciences. stem cells. Additional Glycotope products include TrasGEX, which has successfully completed its phase I/IIa trial and the improved fertility hormone FSH-GEX, which is expected to begin two phase III clinical trials in 2014. Biopharmaceuticals company NOXXON Pharma is a pioneer in the development of a new class of proprietary therapeutic agents called Spiegelmers, which are chemically synthesized L-ste- therapy field, opens a central European production facility in Berlin-Buch +++ ProBioGen upholds strong patent position in viral vaccine manufacturing field NOVEMBER 13 Glycotopes Fully Human and Glycooptimized Recombinant FSH-GEX exhibits superior activity and excellent tolerability in phase II clinical trial for in vitro fertilization +++ The methylated SHOX2 biomarker from Epigenomics shows promising results for therapy-related monitoring of lung cancer patients +++ SCIENION s sciflexarrayer receives product technology innovation award from Materials Science Society AVS +++ The NeuroPro Alliance, a joint venture between the Technical University of Applied Sciences Wildau, nanopet Pharma GmbH and AudioCure Pharma GmbH, receives research award. DECEMBER 13 OMEICOS Therapeutics: new drug for atrial fibrillation in model systems tests positively +++ Contichrom systems from KNAUER receive Berlin-Brandenburg Innovation Award +++ ProBioGen announces expansion of commercial licenses with emergent biosolutions for AGE1.CR viral vaccine manufacturing production platform JANUARY 14 Improved diagnostics for sepsis-associated liver dysfunction with LiMAx test from Humedics GmbH +++ Epigenomics starts trading on US OTCQX market +++ Cell Medica announces European Union orphan drug designation for Cytovir ADV +++ ward-winning Ostendum Lab-on-a-Chip nanodevices are produced with SCIENION's sciflexarrayer SX FEBRUARY 14 The Swedish-German company Amal Therapeutics SA has acquired investors for a seed financing round +++ mivenion GmbH receives FDA approval for Xiralite Fluorescence Imaging System X4 for microcirculation visualization +++ 15 million for Mologen MARCH 14 Glycotope GmbH raises 55 million +++ FDA Advisory Committee Provides Recommendations for Epigenomics' Colorectal Cancer Screening Blood Test APRIL 14 Alacris Theranostics GmbH announces partnership with Walldorfer SAP AG +++ On May 14, Bayer HealthCare opened its first German CoLaborator in Berlin-Mitte on the company's premises +++ Bayer Pharma AG participates in the High-Tech Startup Fund II +++ International pharmaceutical company Takeda extends production facility in Oranienburg 5

BioTOP-Report Biotechnology reoisomer RNA aptamers and a non-immunogenic alternative to antibodies. NOXXON is approaching the completion of multiple proof-of-concept studies with a diversified portfolio of clinical-stage Spiegelmer therapeutic agents exhibiting high safety and tolerability, and promising signs of efficacy. Emapticap pegol (NOX-E36), an anti-ccl2/mcp-1 Spiegelmer, is currently in a phase IIa study in patients with diabetic nephropathy. Olaptesed pegol (NOX-A12), an anti-cxcl12/sdf-1 Spiegelmer, is currently in phase IIa studies in two hematological cancers: multiple myeloma and chronic lymphocytic leukemia. Lexaptepid pegol (NOX-H94), an anti-hepcidin Spiegelmer, has shown efficacy in a subset of anemic cancer patients with functional iron deficiency in a pilot study where the pharmacodynamic parameters of iron metabolism and erythropoiesis were positively influenced and hemoglobin levels increased following lexaptepid mono-therapy. The product will also be evaluated in a phase IIa study in dialysis patients with ESA-hyporesponsive anemia. 2.500 2.400 2.300 2.200 2.100 2.000 1.900 1.800 1.700 1.600 1.500 1.400 1.300 1.200 1.100 1.000 900 800 700 600 500 400 300 200 100 Number of employees Number of Employees According to Company Size 602 1.542 2.442 0 '04 '05 '06 '07 '08 '09 '10 '11 '12 '13 '04 '05 '06 '07 '08 '09 '10 '11 '12 '13 '04 '05 '06 '07 '08 '09 '10 '11 '12 '13 139 companies 1-10 employees 74 companies 11-50 employees 19 companies > 51 employees In comparison to the previous year, the average number of employees per company decreased by 9,2 % in the 1-10 category and increased 15,9 % in the 11-50 category. The average number of employees in the category > 50 employees increased by 3,7 %. (Source: Own survey, BioTOP database, 232 companies questioned, February 2014) 6

BioTOP-Report Biotechnology Epigenomics, a molecular diagnostics company in the process of developing and commercializing a pipeline of proprietary products for the screening and diagnosis of cancer, announced the outcome of a meeting of the Molecular and Clinical Genetics Panel of the FDA s Medical Devices Advisory Committee held in conjunction with its premarket approval for its blood-based colorectal cancer screening test Epi procolon. The members of the Medical Devices Advisory Committee voted favorably, determining that the benefits of Epi procolon do outweigh the risks for use in patients who meet the criteria. Caprotec bioanalytics and Syngenta International AG announced a joint research agreement in which Syngenta will gain access to caprotec s proprietary capture compound mass spectrometry technology. The companies will work together to profile the interactions of one of Syngenta s novel active compounds with the proteome in its relevant plant biological system. caprotec s platform enables the unbiased evaluation of the interactions of small molecules with protein mixtures in a targeted and directed manner, which facilitates the identification and elucidation of tractable targets and accelerates the development of promising leads. Cell Medica announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products has issued a positive opinion on an application for orphan designation of a novel T cell immunotherapy under development by the company. The cell therapy Cytovir ADV targets the treatment of adenovirus infections in patients following allogeneic hematopoietic stem cell (bone marrow) transplant. It is comprised of adenovirus-specific T cells derived from allogeneic donor leukocytes, expanded ex vivo. 5.000 4.500 4.000 3.500 3.000 2.500 2.000 1.500 1.000 500 0 Number of employees Employees in Biotech SMEs '04 '05 '06 '07 '08 '09 '10 '11 '12 4.586 Employment rose to 4.586 in 2013. This is a growth of 5,6 % in comparison to the previous year. The number of companies went up to 232, reflecting the arrival of 24 companies (18 start-ups) and 14 departures. (Source: Internal survey, BioTOP database, 232 companies questioned, February 2014) '13 co.don is one of the world s leading specialists in the cultivation of cells for the joint-preserving treatment of articular cartilage and intervertebral disk defects. Using the company s patented therapeutic products, doctors are able to avoid joint and intervertebral disk prostheses in many cases. An increasing number of orthopedists, orthopedic surgeons and neurosurgeons are relying on this regenerative therapeutic procedure. This minimally invasive method for articular cartilage regeneration has been successful with approx. 6,000 patients in Germany. Experts estimate the overall European market to have a potential annual worth of approx. 1.2 billion. With its current infusion of capital, co.don is paving the way for the EU-wide approval of its biological therapeutic co.don chondrotransplant DISC an autologous method for treating intervertebral disk damage. MetrioPharm was able to complete the regulatory pre-clinical study package. The most important outcome was MP1032 s superior safety profile as confirmed by the results from the various regulatory pharmacology and toxicology studies conducted throughout the past year. The results of these tests surpassed all ambitious expectations. Repeated daily administration of up to 150(!) times the normal therapeutic dose for 28 consecutive days did not cause any side-effects or adverse events whatsoever. A clean safety profile is a highly valuable asset for a new drug. With the impeccable animal safety data obtained for MP1032 an important foundation for entering clinical Phase I trials in 2014 was laid. For the first time, MP1032 can now be tested directly in humans. 7

BioTOP-Report Biotechnology ProBioGen is an internationally operating technology provider and contract development and manufacturing organization (CDMO) with almost 20 years of experience in cell culture, process development and GMP manufacturing. A competent and reliable CDMO partner, ProBioGen offers customized solutions for even the most challenging development and manufacturing requirements. ProBioGen has signed its latest GlymaxX ADCC technology deal with a top-10 pharmaceuticals company for a therapeutic antibody platform. Investment in the Region In recent months, these companies have acquired financing of almost 100 million. Glycotope GmbH has led the field with a new financing round of 55 million. Investors have supplied the company with 130 million in the past few years. One of the largest in Europe, the latest round of financing has attracted international attention. It will be exciting to see how Glycotope s future develops. The listed companies have also obtained a new infusion of money. Mologen and Epigenomics have been able to financially safeguard their next steps with new capital increases, for example. High-Tech Gründerfonds (HTGF) and IBB Beteiligungsgesellschaft, one of the most active venture capital financiers in Germany, were among the most responsive financiers in the Dr. Karen Uhlmann COO/Co-CEO Omeicos Therapeutics GmbH Dr. Robert Fischer CSO/Co-CEO Omeicos Therapeutics GmbH early-stage area again in 2013. Subsidies from the states of Berlin and Brandenburg, which contributed project-related funding volumes of 42 Mio. Euro to life sciences companies alone, supplemented private funding. Investment helps not only the companies involved, but is also relevant for the development of the overall biotechnology region, generating useful growth effects above and beyond its benefits to individual companies. Conclusion The Berlin-Brandenburg biotechnology region has enjoyed a constant growth trend for years. The companies in the sector have again proven their competitiveness in 2013/2014. After many years of developing products and conducting the studies required by the certifying authorities, the near future will show whether the investments have paid off. Most of the biopharmaceutical companies are doing so well that is safe to be optimistic, although the risk remains high. The region s pool of highly specialized service providers is only one of the factors upon which this excellent economic development is based. The companies in the sector grow organically and are typically less dependent on external investors. They important sector delivers constant, sustainable growth for the Berlin-Brandenburg region. Relatively strong fluctuation is typical of the still-young biotechnology sector. Established companies go and new ones come to take their place. The high number of start-ups, which ultimately compensate for failed business ventures, is another reason for optimism. To ensure the successful development of these young companies, private investors must actively participate in early-stage financing again. OMEICOS Therapeutics is working on a new drug for the treatment of atrial fibrillation, and would like to implement the clinical development by the end of 2016. The demand for a new atrial fibrillation treatment is high and with it, its commercial potential. All of the medicines available now to the majority of patients have a limited effect, and some of them go hand in hand with highly problematic side effects. Working with their partners at the Texas Southwestern Medical Center, scientists at the Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch have identified a metabolism product of the Omega 3 fatty acid with an anti-arrhythmic effect. Based on this product, they have synthesized drug candidate OMT-33. The fact that the active ingredient can be further developed for commercial use as part of a start-up is due to the very good general conditions existing before the company was even established. OMEICOS received its initial financial support from the MDC PreGO-Bio funds and Helmholtz Enterprise, the spin-off support project of the Helmholtz Association. The company received seed financing through a High-Tech Gründerfonds participation and ProFIt funding from the state of Berlin, which is co-funded with capital from the European Fund for Regional Development (EFRE). With its BioTech Park, Campus Berlin-Buch provides the ideal framework conditions and an outstanding infrastructure for our product development phase. Of course the direct proximity to MDC is essential to our success. OMEICOS and MDC will continue to work in close partnership. And our cooperation with the Campus' BBB Management GmbH also makes the location very attractive for us. 8

vfa bio represents the biotech interests within the German Association of Research-Based Pharmaceutical Companies (vfa). vfa campaigns for the interests of 45 worldwide leading pharmaceutical companies in the fields of health, research and economy. vfa bio seeks to exploit the therapeutic and economic potential of biotechnology to make Germany the leading biotech location in Europe. Medical biotechnology is vfa bio s topic. We primarily deal with: Medical progress provided by biopharmaceuticals - benefit for patients, physicians and society as a whole Access to biopharmaceuticals for patients Business location Germany and regulatory and economic framework for research, development and production of biopharmaceutical Biosimilars Orphan medicinal products (medicines for rare diseases) Advanced therapies such as gene and cell therapy and tissue engineering products Bild: vfa / Martin Joppen

BioTOP-Report Biotechnology Till Erdmann Managing Director Myelo Therapeutics GmbH Dirk Pleimes Managing Director and Chief Medical Officer Myelo Therapeutics GmbH But they will only do so if the general conditions for venture capital are significantly improved. The political decision makers seem to agree on this objective now all they have to do is adopt relevant new laws. The Start-Up Capital is Booming For many years, the Berlin-Brandenburg region has been generating international headlines as the start-up capital of Germany. Hardly a week goes by without a new start-up being founded, a major financing round being concluded or a major corporation committing to act as an accelerator or incubator. The region is booming; it s an international hot spot. However, this has more to do with IT and web-based applications start-ups. We are a young pharmaceutical company that develops new therapies in fields of application with high medical needs. With a clear strategy for developing our innovative active ingredient Myelo001 for treating chemotherapy-induced neutropenia, we have successfully obtained the support of a series of strategic investors, including IBB Beteiligungsgesellschaft, Eckert Life Science Accelerator (ELSA) and Valenta Pharmaceuticals. The German capital region provides a high concentration of science and research, clinics and business, as well as a high quality of life. It is predestined to be a location for pharmaceutical companies. The technology parks and networks that are part of the Healthcare Industries cluster represent an outstanding infrastructure for translating the latest scientific findings into innovative products. 210 200 190 180 170 160 150 140 Market Segments of Companies 204 88% 130 120 110 100 90 80 70 Number of companies 60 50 40 30 20 10 31 14% 45 19% 0 '04 '05 '06 '07 '08 '09 '10 '11 '12 '13 '04 '05 '06 '07 '08 '09 '10 '11 '12 '13 '04 '05 '06 '07 '08 '09 '10 '11 '12 '13 Agriculture/Food White Biotechnology /Environmental Biotechnology Biomedicine Most companies focus on biomedicine. A total of 88 % of companies, focus primarily on development in the areas of new diagnostics, drug development and associated services or technologies. 13 % of the companies are active in the agriculture / food sector, white biotechnology / environmental biotechnology amounts to 19 % of all entries. (Source: Internal survey, BioTOP database, responses from 232 companies, multiple entries, February 2014) 10

AAT TGA CAC ACG TTC GCC GAT AAG GAA GTT ATG GAA CCT GGA CCA TCA CGA TAA AAC GGA CAA TTA CCC GAT TGG AAA ATC GAA ACC GAA TCA GCC AGT CAA GAA GCT TTC GAC TGC GTA TTG CAA GGC CAC CAG TAG CAC ACG TGC GGA ACG ACA TAA ACT GGA ACA AGA TCC AAA GCT TAT TGG AAG TGC CCG CCA STudieS & ConSulTinG GCA TAC CAA TGC ATG CAC GGA AGG TTC GTA TTA ACT AGA GAT CAT TCT AAC CCT TAT AGC GTT ConferenCeS AAG GAG ATC CCC TTG ACC GGC CGG T TT TCC CTC CTG GCG GTG TCA AAT CAG TGA CGA CCG TGT ACA ACA BookSTC TCG CCA TAA CGT TGG CTT AAA GCT TAG GCC GCC ACG GAA ACG GGT GAC GGG AAT CCA ACC GAC AGA ATT TGA TV & VideoAC TCC GCA CAT TTG CGA GCT AGA ACG TAA GCC TAG GCT CAA AAC GCA TGT GCC GAT CAA GAA TGC AAG GAT CorporATe publishing T TT GGA GAA CTA ACA TCT AGA ATC CAG CTT ACC AGA TGC AAG ATC TTG GGA GGC ACT GAG GTA internet CTC CGC ACG TCC AAT GGA ATC GTA TAA CCA AGG GTT TCC ACA GCC TGA GCC GAT ATC GTA AGG TGA CAA GAA MAGAzineSGA TTC GTC CTC AGT ACG TCA TAG CAA ACT CAC TCA ACC CAA GGA GTT GTA CTA CTG CGC GAA CTT ACG CGA event MAnAGeMenT TA GCG TCG ACG CAC CAA TGC ACC GCC AAC GCC CAG TCC ATT AGA GAG TCA TAA GAC GCA GCA CAA CAC GCT GTT CCC GGA TGC ACA GCC AGG ACT CTT TGC AGC GGC AAA GCA CAT CCA AGA GAA TGG GAC ACG TGC CAC ACC GGC GCA TGT TGA CAC AAT CAG CCT GAT TAG CAC CAG TAA GCT AGA CAA ACA TCT We CreATe know ledg e! TGG AGT G TT CTC AAG GAA TGA CGA TGT GCC TTG ACC TCG ACG GTT ACT ACG TCC TGC ATG TTG CGA TTG GGA AGA AAA CTC BIOCOM AG Lützowstraße 33 36 10785 Berlin Germany www.biocom.de Tel. +49 (0)30 264921-0 Fax +49 (0)30 264921-11

BioTOP-Report Biotechnology Does this status relate at all to start-ups in the life sciences? At first glance, perhaps not. But take a closer look: The large number of players (founders, investors and incubators), the university support programs and many start-up competitions, and the range of various activities create a start-up-compatible atmosphere, which has a positive impact on the start-up scene in the life sciences. Putting it simply, the spillover effect is high. There have not been as many life sciences start-ups in years as there were in the last half of fiscal year 2013/2014. And the striking thing about them is that some of the new companies are focusing on new drug development. Here are a few examples of recent start-ups and their concepts: OMEICOS Therapeutics is a spin-off of the Max Delbrück Center for Molecular Medicine. It develops synthetic compounds with Our Business: Committed to Improving Health 12 For more than 230 years, Takeda has been serving society with innovative medicines. Now, with new healthcare solutions from prevention to care and cure, we are determined to help even more people enjoy their lives to the fullest. Of our 30,000 employees worldwide, 1,700 are working in Germany to develop, produce and market a broad range of medicines to help patients reclaim valuable moments of life from illness. innovative modes of action for the treatment of various human diseases. The company is working on a new drug for the treatment of atrial fibrillation, the most common type of human cardiac arrhythmia. Myelo Therapeutics has developed a drug for the prophylactic treatment of post-chemotherapy patients whose blood contains too few white blood cells (neutropenia) or platelets (thrombocytopenia). Venture capital investors IBB Beteiligungsgesellschaft with their VC Fonds Technologie Berlin, Eckert Wagniskapital und Frühphasenfinanzierung and JSC Valenta Pharmaceuticals are in the company s financing consortium. Amal Therapeutics, a company with facilities in Geneva and Berlin, is developing a vaccine consisting of a recombinant protein with a cell-penetrating peptide acting as a vector. The unique property of this platform is its ability to trigger a highly integrated, multi-epitopic cellular immune response to cancer cells. DexLeChem, a TU Berlin spin-off, provides development services to the chemiwww.takeda.de

BioTOP-Report Biotechnology Financing and Added Value Venture Capital for companies in Berlin cal-pharmaceutical industries for making production processes more chiral, meaning to convert substances with spatially complex designs into water-based processes. The catalyst is not modified before re-use. With this resource-conserving reaction process control, customers drug and fragrance manufacturers benefit from more cost-efficient, environmentally friendly production processes. GlycoUniverse is a technology spin-off of the Max Planck Institute of Colloids and Interfaces. The company specializes in the automated development and synthetic production of complex sugars. With GlycoUniverse s state-of-the-art oligosaccharide synthesizer GLYCONEER, the process of synthesizing complex carbohydrates that formerly took months or years can be completed in a matter of days or even hours. The high number of start-ups is the result of a critical mass of players, activities and initiatives in the start-up area, its welldeveloped infrastructure and excellent location factors as well. These include the seven biotechnology parks that make affordable laboratories and technical infrastructure available, and the many scientific institutes that produce highly skilled specialists. The universities join in with comprehensive spin-off support programs, some of which are triggered by the federal government s EXIST-Gründungskultur - Die Gründerhochschule competition. Pharmaceuticals giant Bayer Healthcare has also discovered the region s potential, providing the technical infrastructure, professional support and expertise of an established pharmaceuticals company to young companies via its CoLaborator, opened in May. Another important element is the many business plan competitions in which founders receive initial feedback for their business concepts. With 140 events, a network of over 200 consultants and over 500 business plan submissions per year, the Berlin-Brandenburg Business Plan Competition is one of the largest competitions of this type in Germany. IBB Beteiligungsgesellschaft mbh offers equity financing for high tech companies in Berlin. For our fund VC Fonds Technologie Berlin ( 52m) we are looking for investment opportunities in the biotechnology and medical technology sector. Our investment approach is based on hands-on involvement and active management support for each portfolio company, delivered by our highly experienced investment team. VC Fonds Technologie Berlin not only provides capital, but also helps execute the business plan. Are you interested? Please do not hesitate to contact us. IBB Beteiligungsgesellschaft mbh Mrs. Ute Mercker / Mr. Christian Seegers Bundesallee 210 10719 Berlin / Germany Phone: +49 (0)30 2125-3201 www.ibb-bet.de The momentum in the Berlin-Brandenburg region is powerful especially at the interface of IT and the life sciences. There are a variety of names for this new area, including ehealth, ithealth, dhealth and mhealth. What they all designate is the successful fusion of the two fields, facilitated by web-based applications in the medical sector. This development is still young, but with its unique density of IT and life sciences players, the Berlin-Brandenburg location is particularly suitable for generating new companies. The first companies have already been founded; take Caterna, an online school for visual exercises, or NeuroNation, the new digital brain-jogging platform for example. There are many new companies in this new field, and in XL Health, it even has a financially strong investor specialized in digital health. Selected portfolio companies: VC Fonds Technologie Berlin was set up as a joint initiative of Investitionsbank Berlin (IBB) and the State of Berlin. It is co-financed by the European Regional Development Fund (ERDF). 13

BioTOP-Report Pharma Pharma Attractive Location The capital region has developed into one of Germany s most important, attractive centers for the medical and healthcare industries. Based on the significant growth of the pharmaceuticals industry in Berlin, these sectors are the growth engine of the regional industry. Currently, the sectors employ approx. 10,000 people in the German capital region. This means that pharmaceuticals companies account for around one in every 10 jobs in the regional industry and every 11th employee in the pharmaceuticals sector in German works in Berlin. Above all, the sectors benefit from the capital region s excellent scientific environment and clinical research landscape, the proximity to decision-makers in the healthcare system and the ready availability of well-educated skilled specialists. A steadily growing number of global players and medium-sized companies are setting up business here or moving their corporate headquarters to Berlin and the capital region, to take advantage of these location assets. With over 220 companies, Berlin is also a leading global location in the biotechnology sector and the pharmaceuticals industry has created a close, innovative network with these partners. The Berlin-Brandenburg region has an outstanding position in several sectors that the experts certify as having a strong growth outlook due to their excellence in innovation. The pharmaceuticals sector's innovative excellence pays doubly for Berlin-Brandenburg, which is also one of the country's leading research locations. The partnership between pharmaceuticals companies, clinics and hospitals and scientific institutions guarantees ultra modern patient healthcare of a uniquely high quality, and the innovations of the pharmaceuticals companies are creating and securing the jobs of the future for the region. The current investment and activities of the local pharmaceuticals sector are proof of Berlin's appeal and bear witness to the companies' commitment to the capital region. Bayer has paid billions to conclude the takeover of Norwegian cancer treatment specialists Algeta. Bayer made the move to strengthen its position in the tumor medication area. The company is also increasing its commitment to young, innovative technology companies. In May 2014, it launched the CoLaborator incubator program. An incubator model for biotechnology start-ups, CoLaborator was tested in San Francisco (Mission Bay) two years ago. In the specially equipped research building, up to 10 innovative biotechnology companies can now get to work thanks to Bayer. Globally active corporations are located along the Spree River: Bayer Healthcare, Berlin-Chemie, Pfizer Deutschland, Sanofi Deutschland and since 2011, Takeda. The capital region is also home to over 20 medium-sized pharmaceuticals companies, including several world market leaders. Within the next two years, Berlin-Chemie will invest 40 million in the expansion of its location, continuing to develop its position as one of the sector's leading employers. Dr. Rainer Uppenkamp CEO Berlin-Chemie AG In Berlin, we find an excellent scientific and commercial environment. This is an important basis for further investments and the expansion of our location in the south-east of the city. In addition required extensions are planned, among others a new building for the quality control, a new staff canteen, an extension of the office capacity for the administrative area and the resulting infrastructural measures in the form of new roads, paths and parking facilities for our employees. 14

You need commitment, focus and passion to find new ways to fight the diseases of this world: innovation is at the heart of it. Innovation for better health. Our commitment is to bring to patients around the world quality medicines for use in diag nosing, combating and preventing disease. Every day we work against time, researching new pathways, new molecules, new technologies complementing our own capabilities with exper tise of innovative partners from science and industry. The success of this work is evidenced in new m e d i c i n e s for areas with significant unmet medicalneed such as oncology, cardiovascular and blood diseases, as well as gynecology and ophthalmology. Our aim is a better quality of life for all. www.bayerhealthcare.com www.bayerpharma.com

BioTOP-Report Pharma Alfonso Casal CEO PharmaMar GmbH Our presence in Germany, the European State Member with the largest population in the EU and strong research capabilities is an important step in our European expansion. From our offices in Berlin we coordinate our commercial operations as well as supporting other corporate activities in Germany. Berlin as Capital city, with important competence centers for the treatment of cancer and strong international orientation represents a very good opportunity for the development of our activities. The partnership between Sanofi and Charité that began in May 2010 with a focus on the area of stroke research has proven fruitful. The partners have signed an agreement to a second joint research partnership, this time with a focus on diabetes. The scientists and clinicians of both parties will also collaborate in a diabetes alliance in the future. The alliance aims to improve understanding of the medical requirements and approaches to the disease of diabetes and, in joint projects, to implement them as therapies and make them available to patients more quickly. After the acquisition of Nycomed in 2011, Takeda moved its German headquarters to Berlin and took over the Oranienburg-based production plant. Oranienburg has a long tradition as a location for pharmaceuticals production. In the past 20 years, the plant there has expanded continuously. It now has a production capacity of 7.6 billion pills and capsules per year 98 percent of which are exported worldwide. The Oranienburg facility is considered one of the main competence centers within Takeda's global production network. Takeda plans to expand the Oranienburg facility's production capacity within the next few years. An important new player, Teva Specialty Medicines, has recently set up business in Berlin. Newly founded Teva Specialty Medicines is Teva Pharmaceuticals' Original Products division in Berlin. Its primary area of success is neurology. Teva is the leader in generics in Germany and an expert in innovative brand business. At a January 2014 press conference in Berlin, Aristo Pharma presented a new formulation of a proven drug for treating severe and extreme pain. The special formlulation was designed for targeted retardation and 24-hour continuous analgesia when taken once a day. Founded in 2008, the company belongs to a growing group of German companies headquartered in Berlin. DR. KADE acquired Takeda s OTC business for the German market in April 2013. With this move, the traditional Berlin company has added well-known brands to its current OTC portfolio and made an investment in the future. In conjunction with the expansion of its OTC business, the company has added new employees in its Berlin and Constance locations. PharmaMar is a Spanish member of the Zeltia Group, a leader in the development of anti-tumor drugs of marine origin. PharmaMar started its activities in Germany in 2007, when the EMA granted it marketing authorization for Yondelis in the treatment of soft tissue sarcomas. Two years later, Yondelis was approved for the treatment of ovarian cancer. In 2013, the company established PharmaMar GmbH in Berlin. These current examples are only an indication of the pharmaceuticals industry activity in Berlin-Brandenburg but they illustrate the extent to which the opportunities here are multi-faceted. They range from close partnerships with regional biotechnology startups and partnerships with science to location expansion and inward investment. The range of opportunities and the strategic options they generate make the Berlin-Brandenburg region highly attractive. Dr. Hans-Christian Meyer Site Manager Takeda Plant Oranienburg Pharmaceutical development and production has a long tradition in the area of Berlin-Brandenburg. The roots of our production plant in Oranienburg trace back to the 19th century. Today, our site plays a pivotal role as a competence center for solid forms such as tablets and capsules within the worldwide pharmaceutical production network of Takeda. The support of the Investitionsbank des Landes Brandenburg helps us to further expand production capabilities, be prepared for future growth and create new jobs. 16

We for the life Modern research, development and manufacturing of innovative medicines in Berlin-Adlershof this is what BERLIN-CHEMIE stands for. Research and production are based not only on our experience of over one hundred years but also on our successful search for new therapeutic pathways and possibilities. The success we have gained around the world and the growth of BERLIN-CHEMIE are an endorsement of our high standards. For more information: BERLIN-CHEMIE AG Glienicker Weg 125 12489 Berlin Phone: +49 30 6707-0 www.berlin-chemie.de

BioTOP-Report Glycoscience Glycoscience Glyco Research for Innovations in Health Industry Alongside genome and proteome research, the study of sugars glycoscience, is increasingly gaining importance. As our knowledge about the function of sugar structures in a variety of biological processes grows, the areas of application for glycoscience are also growing and affecting other fields in the Healthcare Industries cluster such as diagnostics, drug development, regenerative medicine and industrial biotechnology. Sugars can develop complex structures, glycans, and can be even bound to proteins in which case they are called glycoproteins. Glycans are important for a wide variety of biological processes. They control cell-cell communication and the function and stability of proteins, and play an important role in the immune response. Carbohydrate metabolism malfunctions are typically associated with neurodegenerative diseases, infections and cancer. Exploiting high potential for interdisciplinary technologies Glycan structures, as molecules expressed due to illness, can be used as significant diagnostic parameters and can serve as differentiation markers for regenerative medicine. Glycan-based molecules can also be used as vaccines e.g. for malaria and HIV. Glycoscience also contributes to the development of drugs, innovative foods and human-compatible biomaterials. When considering the diverse application fields of glycoscience, it is apparent that the capital region occupies an outstanding position. Berlin-Brandenburg is a technology leader in the chemical synthesis of glycans, and in glycan analytics it offers internationally significant expertise. We also provide excellent conditions for applications in the fields with high cross-innovation potential. The region is a leading international location for research and development in diagnostics and the implementation of clinical studies and also has highly productive drug and nutrition research. With the university hospital Charité Universitätsmedizin Berlin globally acknowledged medical expertise is also present in the region. growth period in recent years and the acquisition of 55 million in venture capital, Glycotope now has over 180 employees and is a world leader in glycobiotechnology. The objective is to turn Berlin-Brandenburg into a leading international center for glycoscience research and translation for the development of diagnostic and pharmaceutical products, cell-based therapies and new materials for medical applications by employing an expansion strategy. We will also be working to intensify the technology transfer based on regional networks and stabilize the communication between science and industry. GlycanForum, the international conference that takes place in Berlin every year, presents the current status and outlook for glycoscience in biomedicine. It is organized with the support of the Center for Molecular Diagnostics and Bioanalysis (ZMDB) and BioTOP Berlin-Brandenburg. The most important conference in the world with regard to glycoscience, GlycanForum is an outstanding open exchange platform for business, industry and users. With a subtheme of "The leading scientists of Asia," the 7th conference in 2013 was focused on the topics of healthcare, material science, analytics and synthesis. Establishing a glyco hub in the capital region Research, whether university-related, independent or clinical, forms the outstanding scientific basis of the region. The Charité has been honing its expertise in the fields of glycoanalytics and glycodesign for many years. The director of the Max Planck Institute of Colloids and Interfaces in Potsdam (MPIKG) and internationally renowned glycoscientist Professor Peter Seeberger discovered and developed the total synthesis of complex carbohydrates. GlykoUniverse, a spin-off company, will distribute the completely automated carbohydrate synthesizer. There are other excellent companies in the region as well. Located in Berlin, Scienion GmbH is distinguished in the field of glycan microarray technology for molecular diagnostics. Glycotope GmbH is specialized in optimizing sugar structures of glycoproteins and developing therapeutic antibodies for cancer cells. In the wake of a strong Dr. Véronique Blanchard Head of Glycoanalytics working group at the Institute of Laboratory Medicine, Clinical Chemistry and Pathobiochemistry, Charité Universitätsmedizin Berlin As a location for glycoscience, the capital region is unique in Europe. You find the entire spectrum here, from basic research to manufacturing industry, which creates the ideal conditions for efficiently translating research innovations to industry and clinics. At Charité, we are researching the potential of glycanbased biomarkers in tumor diagnostics and in bioanalytics for the quality assurance of stem cell preparation, and developing a glycan microarray platform for diagnostics. 18

Corporate Finance Consulting for Life Science Companies With more than 15 years of experience, Portus Corporate Finance supports technology focused companies in all areas of financing. We base our work on solid know-how, years of experience and reliable business partners. Portus Corporate Finance GmbH Friedrichstr. 81 D-10117 Berlin Tel (030) 700 800 900 Fax (030) 700 800 901 Email info@portusco.com www.portusco.com If you are looking for advise and support in the areas of Company and Project Funding Company Succession / M&A Finance Management / CFO-Services Consulting and Coaching Establishment of Businesses please don t hesitate to contact us! UHY Deutschland AG is a joint venture of long established auditing and consulting firms with a total of 250 employees and partners. As a member of UHY International, a global association of independent accounting and consulting firms with over 7,600 employees, we can provide audit, accounting, tax and consulting services in 275 business centres across the globe. UHY Deutschland AG has extensive experience in financial and consulting services for life sciences companies for many years. We offer the following services: Audits of financial and consolidated statements under the German Commercial Code (HGB) and IFRS Accounting & Reporting Due diligence (financial and tax) and business valuations Consulting services on IPOs Business Advisory Mergers & Acquisitions (M&A) German and international taxation We have offices in Berlin/Bremen/Cologne/Frankfurt/Hamburg/Munich/Stuttgart For further information please contact Dr. Ulla Peters UHY Deutschland AG Wirtschaftsprüfungsgesellschaft Zimmerstraße 23 10969 Berlin Phone +49 30 226593-0 Fax +49 30 22679050 www.uhy-deutschland.de www.uhy.com

BioTOP-Report Bioelectronics Bioelectronics The Joint Lab Bioelectronics A New Platform for the Integration of Microelectronics into Life Sciences The introduction of new experimental techniques causes a major advantage in the field of biology. Well-known examples are the invention of optical and electron microscopy, without which the fundamental structures of life as cells and cell organelles could not have been discovered. The next paradigm shift may very well be triggered by applying microelectronics and its developing field of bioelectronics at its interdisciplinary interface with the life sciences. This positive outlook is mainly a result of the phenomenon called scaling in microelectronics: for the last few decades, minimum feature dimensions have continuously become smaller by a factor of around two every second year. At first glance, this seems to be a minor development relating to an uninteresting technical parameter, since we have become accustomed to working with increasingly powerful computers and to storing higher and higher data volumes on a single flash memory. For the life sciences, however, scaling is a major advance. It has taken microelectronics or more accurately, nanoelectronics, to the same structural levels at which the molecular mechanisms of life operate. Particularly interesting perspectives arise for biosensorics, in which semiconductor preparation technology can be applied to the fabrication of cost-effective diagnostic systems. Bioelectronics is also significant for the process analytical techniques (PAT) for monitoring, regulating and increasing the efficiency of bioprocesses. The Berlin-Brandenburg region is eager to take advantage of this development and therefore, IHP in Frankfurt (Oder) and the TU Berlin Institute of Biotechnology have founded Joint Lab Bioelectronics. This step will intensify the interdisciplinary exchange between the two disciplines and expand biotechnology students knowledge of the basics of microelectronics. Prof. Dr. Peter Neubauer Technische Universität Berlin Institute for Biotechnology Chair for Bioprocess Engineering The Joint Lab Bioelectronics aims to advance the field of Bio- Process Analytical Technologies by connecting sensor specialists and bioengineers. JANUARY 2013 Charité and FU are jointly successful in the competition "EXIST-Gründungskultur Die Gründerhochschule" of the German Federal Ministry of Economics and Technology +++ German Research Foundation extends collaborative research centre (SBF 650) at Charité ten million Euros for research on immunological therapy FEBRUARY 2013 Humboldt research award gets Ivy-League professor Klaas van Wijk to Potsdam +++ Biopolymers strong future field with high potential for innovation presents itself in Schorfheide MARCH 2013 Hasso-Plattner-Institut speeds up personalised medicine with new data bank technology +++ Integrative Research Institute for Life Sciences (IRI) founded in Berlin +++ Paul Ehrlich- and Ludwig Darmstaedter Prize goes to MDC scientist Dr. James Poulet APRIL 2013 Charité and Sorbonne found Virchow-Villermé Centre for Public Health +++ EU- OPENSCREEN included in the new BMBF-roadmap for large research infrastructures MAY 2013 New laboratory building of MDC opened named after physiologist Max Rubner +++ Stem cell researchers in Germany pool their expertise. They found the German Stem Cell Network (GSCN) on May 7 th 2013 +++ Evaluators praise Berlin Institute of Health (BIH). Enst Theodor Rietschel becomes chairman JUNE 13 BIH officially opened +++ Charité Universitätsmedizin Berlin once more reaches rank 1 of Focus-ranking "Germany's best hospital" JULY 2013 Prof. Angelika Eggert receives Einstein professorship and takes over as head of the Children's Clinic with focal areas of oncology and hematology +++ Scientists from the A*STAR Genome Institute Singapore and the Max Planck Institute for Molecular Genetics (MPIMG) in Berlin decode the communication network in human embryonic stem cells +++ Scientists from Charité and the MDC, working in cooperation with colleagues in Kiel, Boston, Zurich and London, discover a new gene for hereditary heart failure +++ Scientists working with Peter Seeberger (MPIKG) in Potsdam-Golm have developed a simple, cheap and reliable test for Yersinia pestis, the bacteria that caused the plague AUGUST 2013 1000th protein structure decoded at BESSY II +++ The World Health Summit 2013 in Berlin in August 2013 discussed solutions for global healthcare with regard to Research and Innovation. +++ BPI and vfa present national plans of action for the quick diagnosis and more effective treatment of rare diseases SEPTEMBER 2013 Scientists at Charité and MDC discover sugar withdrawal as an innovative cancer therapy approach +++ Technische Universität Berlin and Leibniz Institute IHP Frankfurt (Oder) have established Joint Lab Bioelectronics, a laboratory for joint interdisciplinary research +++ Charité and Harvard sign a cooperation agreement aimed at accelerating clinical translation, primarily in the cell and tissue technology field +++ Prof. Annette Grüters-Kieslich, Charité Dean, receives the 20

BioTOP-Report Bioelectronics PD Dr. Mario Birkholz Head of Joint Lab Bioelectronics IHP GmbH Leibniz-Institut für innovative Mikroelektronik By establishing the IHP and TUB Joint Lab Bioelectronics, we have created the opportunity for a successful interdisciplinary partnership. Through it, we will be able to translate the progress made in microelectronics directly into biotechnological applications and university education. The Leibniz Institute IHP Innovations for High Performance Micro electronics in Frankfurt (Oder) is part of the Leibniz Association and has a long tradition in the area of silicon-based microelectronics. The IHP has a clean room at its disposal for the pilot serial production of 200-mm Si wafers in which microchips are processed at the 0.25 and 0.13 µm structure levels. A family of SiGe: C-based hetero bipolar transistors for realizing frequencies in the low 100 GHz range is the core of IHP technology. As part of IHP s multi-project wafer services, external customers may use the technology for the fabrication of application-specific integrated circuits. The TU Bioprocess Engineering chair conducts research on the characterization of industrial-scale bioprocesses and methods for consistent, faster bioprocess development. The chair runs a bioprocess pilot plant with advanced analytical instruments, on-line instrumentation and an analytical laboratory for comprehensive metabolomics analysis. Its key instruments are proprietary, scaledown two- and three-compartment bioreactors, which enable the simulation of large-scale industrial processes in the lab. The characterization of biogas plants, brewery reactors and reactors in industrial biotechnology with new PAT and model-based process control for improving their robustness are a major focus. For this highest honor offered by ESPE, the European Society for Paediatric Endocrinology: the Andrea Prader Award +++ New Helmholtz post-graduate school for researching biomaterials opens OCTOBER 2013 Fraunhofer researchers receive an international award for ArtCornea, their artificial cornea +++ The capital has healthcare in focus: Berlin Health Week celebrates its launch +++ Sanofi endows two new professorships in the public health field at Centre Virchow-Villermé, the newly established German-French research institute, in its Berlin and Paris locations +++ Charité opens the intensive care station of the future NOVEMBER 2013 NeuroProAllianz receives Technical University of Applied Sciences Wildau research award Dr. Jean-Yves +++ K. Tano from the University of Toledo arrives in Berlin after receiving an Alexander von Humboldt fellowship +++ Charité coordinates the national network of biobanks +++ Immunologist Prof. Klaus Rajewsky from MDC Berlin awarded the Society for Signal Transduction medal of honor DECEMBER 2013 Charité opens pioneering robotics operating room +++ Scientists from Charité present new approaches toward improving breast cancer therapy as part of the RESPONSIFY EU research project JANUARY 2014 Under the leadership of Cornelia Weikert from the German Institute of Human Nutrition (DIfE), a team of scientists has discovered a new biomarker for heart failure in the general population +++ Researchers at MDC Berlin have acquired new knowledge of the body's regulation of insulin production for insulin resistance, the root of type 2 diabetes +++ The biochemist and protein crystallographer Prof. Oliver Daumke from MDC Berlin-Buch receives European Research Council funding worth millions +++ BTU Cottbus-Senftenberg strengthens biomaterials research network with Helmholtz Center Geesthacht in Teltow FEBRUARY 2014 MPIKGPotsdam director Prof. Peter Seeberger and the director of the NII in New Dehli, India agree to intensify their partnership for researching infectious diseases +++ Researchers at MDC decipher the creation of new forms of hereditary Alzheimer s disease and discover new protective mechanisms +++ Researchers at the Max Planck Institute for Moldcular Plant Physiology in Potsdam-Golm discover new adapter proteins for the reception of substances in plant cellss +++ The Berlin Institute of Health (BIG) acquires Thomas Südhof, Noble Prize for medicine co-awardee, as visiting fellow MARCH 2014 Two dozen Fraunhofer Society institutes establish the Big Data Alliance +++ MDC receives 3-Tesla MRI scanner for the largest long-term German population study +++ MDC researchers discover the molecular switch for epilepsy APRIL 2014 Berlin Institute for Health Research launches first research projects +++ Hans- Hilger Ropers awarded with the EURORDIS Scientific Award 2014 for his research on rare diseases 21

BioTOP-Report Bioelectronics purpose, new lance- and rope-based mobile sensor and sampling systems that can be directly applied to analyze concentration gradients have been developed. A robot-based mini pilot plant has also been established for process development in micro-plate and mini-bioreactor cultures. This highly automated facility focuses on processes with genetically engineered microorganisms. Extensive analyses are automatically performed on tens to hundreds of cultivations in μl and ml formats. The laboratory pioneered the EnBase controlled substrate delivery technology, which is instrumental for consistent bioprocess development and a key element in this high-throughput (HT) automated industrial reference laboratory. Joint Lab Bioelectronics mission is to introduce new biosensor technologies. This work focuses on the adaption of the sensor system to the particular biotech application. The starting point is the sensor chips developed at IHP, including a fully embedded microelectromechanical system (MEMS) for affinity assays and a cell sensor operated via impedance spectroscopy (see Fig. 1). However, the biochips fabricated in semiconductor fabs require special packaging before being introduced into bioprocesses with an emphasis on hermiticity and must be shielded against corrosion from the liquid bio milieu. switching time t sw (ms) 150 140 130 120 110 100 90 80 30º 35º 40º T dependence of t sw in sensoric fluid for varying c g glucose concentration c g (mm) Figure 1. Affinity-viscosimetric microsensor chip with fully embedded MEMS (X-shaped beams on the left) und calibration curves for glucose concentration measurements it has taken, Birkholz et al., J. Appl. Phys. 113 (2013) 244904. The demand for microsensors for applications in microfluidic platforms has jumped in recent years. Many applications rely on polymer devices, because most companies and scientific working groups have almost no access to microelectronic fabrication techniques. Joint Lab Bioelectronics follows the approach of developing and supplying biotechnological platform modules that combine equal shares of microelectronic and microfluidic components. Bioprocess engineering is one promising field of application for miniaturized sensors. Industrial bioprocess development faces the challenge of reducing the risks, costs and timeframe of new product launch. In the pharmaceuticals industry in particular, the regulatory authorities expect dossiers to be based on knowledge that derives from careful sensing (PAT). Consequently, future bioprocess development will consist of HT technologies based on miniaturizing, parallelization, automation and intense monitoring. Joint Lab Bioelectronics is a perfect match for the Bioprocess Engineering chair s HT lab, where platform technologies are developed to comply with the above-mentioned needs. This lab is Joint Lab Bioelectronics miniaturized sensors EnBase Robotics MagReSyn TM DoE Sensors Integration Fed-batched in μl and ml scale Automated cultivation Automated DSP and analytics Experimental plans, modelling On-line data reading Automated data evaluation Figure 2. Steps in consistent, automated bioprocess development based on process analytical technologies, experimental design approaches and the early consideration of the industrial process by applying the fed-batch mode. 22

BioTOP-Report Bioelectronics able to screen volumes of as little as 200 µl per vessel, in up to 96 vessels at the same time. Process development and production process characterization take place simultaneously, in up to 48 miniaturized stirred-tank bioreactors with a working volume of approx. 10 ml. The cultivation, process analytics and product recovery processes are automated with the help of a liquid handling system (lab robot). In close collaboration with Joint Lab Bioelectronics, the scientists explore the application and integration of microsensors for glucose concentration and cell density in HT systems. The overall process development approach relies on consistency: experimental planning determines parameter fields, production systems are investigated under process-related conditions and IT tools handle data. These platform technologies are currently being applied to specific demonstrator processes. Interested customers can also take advantage of the HT lab s services. Last but not least, Joint Lab Bioelectronics aims to teach microelectronics to Biotechnology students, since the job markets of the the future will demand large numbers of graduates specialized in this field. The Introduction to Bioelectronics course was introduced in 2012 and has been held every summer semester since then. It was recently included as a mandatory elective course in the Master of Biotechnology program at TU Berlin. For the second year in a row, Joint Lab Bioelectronics will organize a bioelectronics symposium in September 2014, where leading experts in the field will discuss their recent developments. IHP will present its biotechnology-relevant technology modules during the second day of the symposium. We cordially invite interested colleagues from the life sciences and microelectronics to participate in the symposium. Achieve innovation, shape the future Start shot for young technology companies High Tech Gruenderfonds is your partner for Seed Stage investing. We help out young, high potential startups in the early phases of technology and product development, as well as successful launching. Our assistance is not limited to our cash investments, instead we strive to add long term added-value to portfolio companies through our extensive network of professional and our accredited coaches. High-Tech Gründerfonds Management GmbH Software Internet & Telecommunication Media & E-commerce Life Science Materials Science Nanotechnology & Chemistry Energy Automation Photonics Industrial Software Schlegelstraße 2 53113 Bonn Phone: +49 (0)228-823001-00 Fax: +49 (0)228-823000-50 E-Mail: info@htgf.de http://www.high-tech-gruenderfonds.de INVESTORS OF HIGH-TECH GRUENDERFONDS II 23

BioTOPics 47 6. Juni 2014 (3:02) BioTOP-Report Business Location Business Location Excellent Services for Berlin-Brandenburg The Berlin-Brandenburg region harbors outstanding potential for technological development and cooperation in its high-density landscape of scientific and research institutions. The high concentration of international excellence here facilitates interdisciplinary exchange, making it easier to realize new, landmark developments. At the same time, the sheer number of players can make it difficult to find the right partner. The region s Inward Investment and Expansion team supports the healthcare and life sciences sectors with a full range of services, including marketing activities at national and international trade shows. Our team has been in direct contact with the region s companies and scientific institutions for many years and can provide quick access to the right contacts and potential partners. In 2013, Berlin Partner for Business and Technology supported expansion projects and provided location services to 33 companies in Berlin, generating around 320 new jobs and a projected investment of 63.9 million within the next three years. The list of companies includes Cell Medica, CBR Biotech Strategies, Amal Therapeutics and G&Life, an Italian company. As in previous years, we organized a Berlin-Brandenburg Night to mark the opening day of the BIO conference and exhibition in Chicago. Once again, Bayer HealthCare was the lead sponsor. Accepting the invitation from HealthCapital and Bayer HealthCare, around 400 international guests from biotechnology and pharmaceutical companies attended the event. In the same year, the Brandenburg Economic Development Board (ZAB) supported approx. 130 investment and innovation projects in the healthcare sector with a total investment volume of around 27 m and the potential to create 220 new jobs. The successful location of technology-based start-ups such as Glyco Universe, ai-ibiomics and medneo deserves special mention. The team at ZAB also supported the expansion investments of resident companies co.don and Seramun. With the aim of positioning the region s companies in the global markets and presenting the Berlin-Brandenburg Healthcare Industries cluster HealthCapital as one of Europe s leading healthcare sector locations, the region exhibited at four important international fairs in 2013. Dr. Rainer Knaus Senior Vice President Cell Medica Ltd. Cell Medica, a leading T-cell therapeutics company and pioneer in the field, acknowledges the importance of the German market and especially the excellent conditions in Berlin. The European commercial manufacturing facility within the Campus Berlin-Buch biotechnology park was designed and equipped to facilitate the high quality GMP-compliant production of patient-specific cell therapies for distribution across Europe. Here in Berlin, we have found an outstanding scientific and industrial environment that allows us to attract highly educated, well-trained personnel who are keen to help shape this new era of cell-based therapeutics. To provide support in the areas of internationalisation, technology transfer and regulatory affairs to companies and scientific institutes already located in Berlin and Brandenburg, we organized more than 30 conferences, workshops and networking events last year. The 2,000 accredited participants came from all over Germany. Berlin-Brandenburg is also a life sciences hot spot for international delegations. At the 2013 BIONNALE, our annual biotechnology conference, a group from Denmark presented its products and services and networked with representatives from regional companies and scientific institutions. In 2013, we kicked off the first Health Week for the capital region. Companies and organisations from the healthcare industries took advantage of the opportunity to showcase their prevention, diagnostics and therapy expertise and services. Over 90 companies and institutions organized more than 300 public events in one week. Carolin Clement Head of Unit Biotech I Pharma Berlin Partner for Business and Technology Phone +49 30 46302-430 carolin.clement@berlin-partner.de www.berlin-partner.de Dr. Ute Hartmann Head of Department Healthcare Industry/ Life Sciences Brandenburg Economic Development Board (ZAB) Phone +49 331 20029-250 ute.hartmann@zab-brandenburg.de www.zab-brandenburg.de 24

Life Sciences. Living Research. Berlin. Brandenburg. A vibrant network. Berlin-Brandenburg is one of Europe s leading locations for the Life Sciences. It is also an R&D capital that magnetically attracts the world s top scientists. Here you ll find attractive funding conditions, close linkages between business and science, the highest concentration of R&D in Europe, a dynamic startup scene and a multifaceted entrepreneurial environment made up of more than 500 pharmaceutical, biotech and medical technology companies. Come discover this one-of-a-kind landscape for scientists and entrepreneurs. www.healthcapital.de

BioTOP-Report Spotlight on European Business and Internationalization Spotlight on European Business and Internationalization The Enterprise Europe Network Berlin-Brandenburg The Healthcare Industries cluster Berlin-Brandenburg has been an active member in a variety of European networks and initiatives for many years. With the launch of Horizon 2020, the new EU research funding program, one network in particular has taken center stage: the Enterprise Europe Network (EEN) Berlin-Brandenburg. With 20 experts on Europe from the three participating host organizations Berlin Partner for Business and Technology, Brandenburg Economic Development Board (ZAB) and the East Brandenburg Chamber of Commerce and Industry, it is the basis for internationalization in the region primarily for small and medium-sized companies. Helping SMEs find business and technology partners throughout Europe, the EEN provides information and advice on the innovation-oriented developments, initiatives and programs of the European Union. The EU Commission initiated the network, which connects 100 regional consortia in approx. 60 countries in Europe and the world to each other, at the beginning of 2008. Over 500 regional economic development institutions, chambers of industry and commerce and technology agencies with a total of 4,000 employees collaborate closely within the network. Supporting small business is a cornerstone of the EU's drive for growth and jobs: 99% of all companies in the EU are small and medium-sized (SMEs) and they account for 67% of the jobs. The EEN s services are tailored to SMEs, but are also available to all other businesses, universities and research centers. Services tailored to small companies Taking part in an EU-funded research project is a great way to boost a company's competitiveness. SMEs need the right partners for successful projects, and the Enterprise Europe Network helps by identifying companies' needs and potential and connecting them with each other. The network does not fund any projects itself, but helps companies to tap into the EU's funding opportunities. Horizon 2020 leads the way it is the EU's latest research funding program, launched in December 2013 with a volume of almost 80 billion. Normally, its consortia must consist of companies from three different EU countries, but the EEN also assists SMEs with this aspect. The network s business cooperation database is one of the world's largest and contains thousands of company profiles. Companies can meet potential business partners in person at EEN s matchmaking events, which often take place at international fairs to help keep travel and accommodation costs low. For example, the Enterprise Europe Network Berlin-Brandenburg played a major role in opening up the annual BIONNALE the key biotechnology and pharmaceutical industry meeting place in the capital region to an international audience. Almost 80 participants, including a larger company delegation from partner country Denmark, gathered for the matchmaking event EEN organized in 2013. On the day of BIONNALE 2013, the participants held around 160 meetings. The regional EEN contact point for all themes relating to the healthcare industries: Wolfgang Korek Project manager EEN Healthcare Industries Phone +49 30 46302-518 wolfgang.korek@berlin-partner.de www.berlin-partner.de Elias Zafirakos Science & Innovation Network Manager Biopeople Københavns Universitet The matchmaking session organized by the Enterprise Europe Network gave the Danish delegation a valuable opportunity to meet with potential German collaboration partners at the Bionnale 2013. The EEN setup made it possible to plan and book meeting ahead of the conference and was a great help in exposing the Danish Delegation towards the German audience. Dajana Pefestorff Project manager International Business Director EEN Phone +49 331 660-3234 dajana.pefestorff@zab-brandenburg.de www.zab-brandenburg.de 26

BioTOP-Report 2014 Alacris Theranostics GmbH Alacris Theranostics GmbH is a Berlin-based company with the mission to exploit next generation sequencing and other omics data through its predictive modelling system Mod- CellTM for drug development and personalised medicine in oncology. This approach was originally developed at the Max Planck Institute for Molecular Genetics in Berlin and is exclusively licensed to Alacris. Unlocking The Power Of Individualised Medicine Alacris provides extensive bioinformatics expertise and well equipped facilities including a next generation sequencing lab for clinical application and a powerful IT infrastructure. Alacris works together with clinics and industry leaders in the fields of personalised medicine, biomarker application, and drug development. With its proprietary ModCell System, Alacris Theranostics applies a new, revolutionary systems biology modelling approach to better match patients to therapies and therapies to patients. ModCell provides a 'Virtual Patient' model allowing predictive analysis of cancer patient samples on therapy outcome. ModCell integrates next generation sequencing derived genome and transcriptome information with a generic cancer model of molecular processes in tumour onset and progression. ModCell facilitates the simulation of the effects of different drugs for the development of new personalized medicine approaches in the clinic and for effective development and approval of drugs for the pharmaceutical industry in 'Virtual Clinical Trials'. Address Alacris Theranostics GmbH Fabeckstraße 60-62 Phone +49 30 84312250 14195 Berlin Germany info@alacris.de www.alacris.de co.don AG The biopharmaceutical company based near Berlin is one of the leading specialists worldwide in cell cultivation for the regenerative treatment of articular cartilage defects and spinal disc defects. In many cases the use of the company's patented pharmaceutical product can avert the need for joint and spinal disc replacement surgery. Orthopaedic, accident and neuro-surgeons are increasingly applying these regenerative treatment methods. co.don AG manufactures cellbased tissue engineering therapeutics to the highest quality standards. Its products represent a revolutionary pro cess in the biological replacement of dam aged articular cartilage and invertebral disc by building up strictly autologous tis sue without the involvement of any external carrier materials or additives. The applica tion of the products may be minimally inva sive or arthroscopic and so surgery and reha bilitation times are significantly reduced for both doc tor and patient. Because no external materi als are used, the risks of rejection, inflamma tion and infection are reduced to the minimum. co.don AG is certified in accordance with DIN EN ISO 9001:2008. Furthermore, pro duction, quality control and quality assur ance have been certified in accordance with European Guidelines for Good Manufactur ing Practice (EU- GMP). co.don AG s technological, production and regulatory expertise makes the company a first mover in the market for biological carti lage and disc tissue replacement and a provider of highly effective, safe treatment options not only resulting in relief of pain, but actual repair of damaged tissue. co.don AG is listed on the Frankfurt Stock Exchange (ISIN: DE000A1K0227). Address co.don AG Warthestraße21 14513 Teltow Germany Contact Matthias Meißner, M.A. Head Corporate Communications/IR/PR Phone +49 3328 4346 0 Fax +49 3328 4346 43 info@codon.de www.codon.de 27

BioTOP-Report 2014 Evestra GmbH Evestra GmbH, founded in July 2008, is a fully owned subsidiary of Evestra Inc. located in San Antonio Texas. Evestra GmbH serves as the development and commercialization center for Europe and ROW. Evestra s mission is to develop and commercialize steroidbased female healthcare products. The development strategy of the company includes product ideas with known compounds as well as New Chemical Entities. Evestra is conducting research and product development in a number of in-demand, but as yet unmet, medical need areas of women s health such as hormonal-dependent breast cancer and endometriosis. The company is also pursuing different projects in fertility control, e.g. a new estrogen for oral contraception, with superior pharmacological properties compared to the standard drug ethinyl estradiol. Address Evestra GmbH Britzer Straße 26 12439 Berlin Germany EU Contact Prof. Klaus Nickisch Managing Director Phone +49 30 66509642 knickisch@evestra.com www.evestra.com Several patents on new composition of matter, new technical processes and use patents have been filed during the last years and support the strong intellectually property position. Evestra is concentrating on R&D and will seek more partners for commercialization. More detailed information can be found on our website. LGC Genomics At LGC we offer a full range of high quality PCR reagents, custom genotyping assays, genomic services and workflow solutions for DNA sample preparation and downstream processing (www.lgcgroup.com/genomics). Our proprietary KASP allelic discrimination chemistry and has optimised workflows for 1536 microtitre plates that enable assay miniaturisation for more flexible, cost-effective workflow solutions in high-throughput genotyping. In addition, customers are offered industry leading proprietary nucleic acid extraction, sequencing and genotyping services from our labs globally. We use what we sell and sell what we use is key to the products and services we provide. Our portfolio includes: kkgenotyping services, assays and reagents kksanger and next-generation sequencing services kk DNA and RNA extraction products and services kk PCR reagents and consumables kk Laboratory instrumentation kk Plate sealers kk Liquid handling robots kk High-throughput PCR thermal cyclers kk Plate readers We operate sales offices in the UK, Germany and the USA, with sales representatives throughout Europe, the USA and Australia as well as distributors in China, Korea and other key emerging territories. Address LGC Genomics GmbH Ostendstrasse 25 TGS Haus 8 12459 Berlin Germany Phone +49 30 53042200 genomics@lgcgroup.com www.lgcgroup.com/genomics 28

BioTOP-Report 2014 Metanomics Health GmbH Metanomics Health a BASF Group company combines comprehensive Metabolite Profiling (metabolomics) with biomedical data interpretation. Metabolite Profiling is defined as the parallel analysis of multiple endogenous and xenobiotic metabolites in biological systems. The core expertise of Metanomics Health resides in discovery and validation of biomarkers. Technologies kk Metabolite profiling platform with more than 75 GC-MS and LC-MS/MS instruments kkwide metabolite coverage via combination of unbiased and targeted platforms kkunique tox mode of action prediction through MetaMap Tox database kk Excellence in systems correlation analysis of complex gene function relationships kk Highly robust and reproducible results Major R&D-Topics In cooperation with academic institutes and clinical experts Metanomics Health is running a large-scale diagnostic biomarker program. Areas include metabolic syndrome, heart failure, prostate cancer and pancreatic cancer to mention a few. Market Segments Metanomics Health provides its services to pharmaceutical, diagnostics and nutrition companies. Technology applications include: kk Mechanism of action studies kk Mechanism of toxicity studies kktranslational and clinical biomarker development (e.g. PK/PD, patient stratification, efficacy and safety markers) kkcompanion diagnostic development kkcell culture & bioprocess optimization kkbiospecimen quality control Address Metanomics Health GmbH Tegeler Weg 33 10589 Berlin Germany Contact Dr. Tim Bölke Managing Director Phone +49 30 34807 400 Fax +49 30 34807 401 company.info@metanomics-health.de www.metanomics-health.de nanopet Pharma GmbH nanopet is a biopharmaceutical company specialized on R&D, manufacturing and marketing of innovative drug substances for Diagnostic Imaging. We focus on relevant cardiovascular, oncological and neurological indications as well as on regenerative medicine. Nanotechnology is a key element of our business. We operate in three major areas. The first nanoparticular tracers for clinical PET: nanopet prepares the clinical development of its patented technology platform: inorganic nanoparticular tracers for cell- and molecular-specific positron emission tomography (PET). Viscover imaging agents a landmark in small animal imaging: As animal imaging is rapidly gaining relevance in pharmaceutical research, we are delighted to offer you an exciting portfolio of specialized pre-clinical imaging agents covering the principal imaging modalities (MRI, CT, Ultrasound, Optical Imaging, SPECT & PET). Get a detailed insight into our product portfolio and download a free copy of our imaging guide on www.viscover.com long-standing industry expertise our team has attained in the pharmaceutical research & development. Address nanopet Pharma GmbH Robert-Koch-Platz 4 10115 Berlin Germany Contact Dr. Andreas Briel CEO Phone +49 30 890 49740 imaging@nanopet-pharma.com www.nanopet-pharma.com Consulting and Service tailored to your needs: As a technology and service provider, we offer our expertise to biopharmaceutical companies and imaging equipment manufacturers. Our customers benefit from the 29

BioTOP-Report 2014 Getting your innovation going. Our tailored financing are your key to success. Our consultants look forward to meeting you. Contact us: Phone: +49 (0)30 / 2125-4747 E-mail: wachsen@ibb.de www.ibb.de/wachsen 140305_IBBanz_biotop12_210x148.indd 1 05.03.14 12:22 ORGANOBALANCE GmbH Exploring and managing microbial biodiversity ORGANOBALANCE explores the potential of probiotic bacteria and yeasts for new product developments in food, feed, personal care, and for the pharmaceutical industry or the production of fine chemicals. From a large collection of microorganisms, specific strains are selected to e.g. inactivate pathogens, produce new bioactives, neutralize malodorous or toxic substances and synthesize high titers of valuable compounds. ORGANOBALANCE draws on natural resources, which are gathered in the company-owned collection of 8000+ microbial strains, mostly originating from foodstuffs. ORGANOBALANCE uses its OASSYS bioassays for highly efficient screenings. The platform allows to quickly identify the most suitable strains from the microbial collection for targeted applications. ORGANOBALANCE has a broad expertise in the field of yeast metabolic engineering. This includes designing and developing new production strains for industrial biotechnology applications. Specific strains of Saccharomyces cerevisiae, which carry engineered biosynthesis pathways for the environmentally friendly production of carboxylic acids, terpenoids, steroids and other lipid compounds are available. ORGANOBALANCE works in collaboration with partners and grants licenses for own product developments. Address ORGANOBALANCE GmbH Gustav-Meyer-Allee 25 13355 Berlin Germany Contact Dr. Christine Lang CEO Phone +49 30 46307200 Fax +49 30 46307210 info@organobalance.com www.organobalance.com 30

BioTOP-Report 2014 syneed medidata GmbH Are you getting the whole picture? We Do. syneed medidata GmbH is an independent, privately owned contract research organization (CRO) providing end-to-end services for phase I to phase IV clinical trials and for noninterventional studies. Commencing business in 1985, we have constantly expanded our service portfolio. In 1995 we conducted our first medical device study, and in the same year we started our Imaging Core Lab operations (see below). Moreover, we offer the complete scope of Pharmacovigilance services for development projects as well as for marketed products (drugs and medical devices). Our notion of service is based on the knowledge that every project is unique and that custom-tailored solutions serve best. This is reflected in all our actions. As an example, for data capture our clients may choose between paper and different EDC solutions, including our proprietary EDC system, which has been developed for multinational non-interventional studies and gets enthusiastic feedback from both customers and end-users. syneed medidata GmbH combines experience with the quality, dedication and flexibility of a midsized organization. Full clinical and biometric services for clinical trials and non-interventional studies Operational services offered in EU, CEE, Russia and USA through our established alliance of partner CROs Very high staff retention - stable, experienced teams delivering projects on time and with highest quality Pharmacovigilance and Imaging services for development projects and marketed products Best value for money due to tailor-made services So, for almost any trial you can think of, we provide the expertise you need for turning data into results. Address syneed medidata GmbH Cicerostraße 21 10709 Berlin Germany Phone +49 30 31172751 00 www.medidata.de info@medidata.de Contact Dr. Christian Hucke Clinical Program Director christian.hucke@medidata.de syneed imaging syneed imaging, the Medical Imaging Core Lab of syneed medidata GmbH, offers solutions for study planning, protocol development, site evaluation, image collection and processing and conduct of central independent reviews with a wide variety of criteria (e.g. RECIST, 1.0 and 1.1, Choi, Cheson, irrc, RANO, PERCIST, mrecist). Within almost 20 years of operation we have managed trials in various indications (oncology, neurology, radiology, PET diagnostics, devices) and modalities, and established an extensive network of medical experts who support us as consultants and independent readers. Our experience, flexibility and pricing especially for early phase trials are highly valued by Biotech clients. All study data are hosted solely in Germany on our servers maintained by own IT staff. Address syneed imaging & syneed medidata GmbH Cicerostraße 21 10709 Berlin Germany Phone +49 30 31172751 00 Contact John Uiters Director Medical Imaging Services john.uiters@medidata.de 31

BioTOP-Report Bioparks Networks Scientific Institutions P Companies Biotech Networks kkbiotop Berlin-Brandenburg kkbiohytec Network for Biohybrid Technologies kkbioresponse kkcenter for Molecular Diagnostics and Bioanalytics (ZMDB) kkdiagnostiknet-bb kknetwork Glycobiotechology Berlin-Brandenburg kkregenerative Medicines Initiative Berlin-Brandenburg kkrina Network for RNA Technologies Scientific Institutions kkberlin-brandenburg Center for Regenerative Therapies (BCRT) kkbrandenburg University of Technology (BTU) kkcharité Universitätsmedizin Berlin kkfraunhofer Institute for Applied Polymer Research (IAP) kkfraunhofer Institute for Biomedical Engineering (IBMT) kkfreie Universität Berlin (FU) kkgerman Heart Instiute Berlin (DHZB) kkgerman Institute of Human Nutrition (DIfE) kkgerman Rheumatism Research Center (DRFZ) kkhumboldt-universität zu Berlin (HU) kkinstitute of Biomaterial Sciences, Helmholtz-Zentrum Geesthacht (Teltow) kklausitz University of Applied Sciences kkleibniz-institute for Agricultural Engineering Potsdam-Bornim (ATB) kkleibniz-institut für Molekulare Pharmakologie (FMP) kkleibniz-zentrum für Agrarlandschaftsforschung (ZALF) e. V. kkmax Delbrück Center for Molecular Medicine (MDC) Berlin-Buch kkmax-planck-institute for Colloids and Interfaces kkmax Planck Institute for Infection Biology kkmax Planck Institute for Molecular Genetics kkmax Planck Institute of Molecular Plant Physiology kkrobert Koch Institute kktechnische Universität Berlin (TU) kkuniversity of Applied Sciences Berlin (HTW) kkuniversity of Applied Sciences Wildau kkuniversity of Potsdam 32

BioTOP-Report IFHI 33

BioTOP-Report Biotech Parks Biotech Parks The BioCampus Network Berlin-Brandenburg Berlin-Brandenburg boasts seven biotechnology parks, which offer optimal space for the specific requirements of every company. This geographic concentration of specific biotech parks is unique in Germany and probably in all of Europe. The parks differ in their offers and strategic focus and provide ideal conditions for newcomers. More than half of the 232 companies are currently utilizing the infrastructure of a publicly or privately managed park. In addition, the young companies benefit from the closeness to science and the permanent contact and exchange. berlinbiotechpark In the very heart of Berlin berlinbiotechpark Management GmbH Herr Frank Elsner Max-Dohrn-Straße 8 10 10589 Berlin Phone +49 30 20364205 Fax +49 30 20364190 info@berlinbiotechpark.de www.berlinbiotechpark.de berlinbiotechpark is located on a 86,000 sq.m. site in the very heart of Berlin, currently offering a total of approx. 63,000 sq.m. of office, laboratory and production space, with a building potential for another 45,000 sq.m. of rental area. The site, which is home to Biotech/Pharma/Service Companies is supplied with a complete range of media for laboratory and production purposes, with production steam with possibility to upgrade to HP steam, power supply, compressed-air, nitrogen and other inert gases, cooling water and DI-water, all being provided at favorables rates. The infrastructure includes conference facilities as well as works security and waste disposal services. It is rounded off by production-related services such as plant engineers and laboratory technicians, industrial safety engineers, a medical service as well as best-buy services and communication services. Offering flexible growth potential, production-orientated media equipment and comprehensive industrial-specific services and infrastructure, berlinbiotechpark is particularly attractive for growing internationally orientated technology companies. Furthermore, it offers a permanent base in Berlin for developing companies that have outgrown the size allowed by their limited start-up funding. The inner-city location and the excellent public transport guarantee short ways to all scientific institutions and hospitals of the city. Biotech Campus Potsdam Research on the Waterfront Biotech Campus Potsdam Steinstraße 104-106 14480 Potsdam Phone +49 331 6601628 Fax +49 331 6601699 info@biotechcampus.de www.biotechcampus.de Contact: Gabriele Ziegler Just a few minutes away from Potsdam s central railway station in the direction of Caputh, Biotech Campus Potsdam is located on the Hermannswerder peninsula in the river Havel. It is owned and operated by Biotech Campus Potsdam GmbH, a fully owned subsidiary of the Investment Bank of the State of Brandenburg. 34

BioTOP-Report Biotech Parks The biotechnology center is housed in four buildings dating from around 1,900 and one modern complex and offers a total of 11,400 sq.m. of laboratory, office, greenhouse and storage space. With such a large facility at its disposal, it offers biotechnology companies an ideal environment for successful operations. All labs are approved as S1 laboratories and meet the building requirements for approval as S2 labs. The Hermannswerder site also includes an S3 laboratory as a special resource. The beautiful, park-like setting of the peninsula offers an excellent environment for research activities. The island hotel and a conference center are located directly next to the campus. The site also includes a self-service restaurant and small island shop. The philosophy of Biotech Campus Potsdam was, and still is, to create the freedom for research and innovation in the high-tech sector of biotechnology. Reputable firms from the industry can indeed be found here. Biotechnology Park Luckenwalde Space for Expansion Biotechnologiepark Luckenwalde c/o SWFG mbh Im Biotechnologiepark, TGZ I 14943 Luckenwalde Phone +49 3371 681100 Fax +49 3371 681105 bio-luck@swfg.de www.bio-luck.de Contact: Dipl.-Ing. Christoph Weber Director Located just 25 miles from the new Berlin-Brandenburg International Airport (BBI) in the district of Teltow-Flaeming, the Biotechnology Park Luckenwalde is one of the most modern facilities of its kind in Germany. It is home to 35 companies from Germany, USA, UK, Korea and Israel with about 500 employees. The work carried out by resident companies is multi-faceted, ranging from green biotechnology, the development of vaccines, the development of pharmacologically active substances based on plant materials, the development and production of PCR tests for food testing and preclinical contract research right through to medical technology. A total of 200 employees work on the site. Companies in the park focus on the development and production of pharmaceuticals, recombinant proteins and diagnostic kits, biological/chemical substances for biotech and pharmaceutical applications, as well as fine chemicals. There are also suppliers of medical technology, analytical services, and a Biotech Education Center. Technical Equipment comprises completely furnished S2 laboratories (safety workbench, autoclave, dishwasher, deionized water, water purification system, central media supply (compressed air, N 2, CO 2, O 2, H 2 ), storage and cool rooms, pharmaceutical clean rooms category 35

BioTOP-Report Biotech Parks (B/C), 400 MHz NMR spectrometer, meeting rooms, conference hall (300 seats), library, restaurant with catering service. start-up funding, we additionally hold 80,000 sq.m. developed industrial property ready for expansion. The entire central technique meets GMP/ISO 9001 specifications. The park management offers comprehensive, individual services and advice during the settlement and development of firms, including support for the recruitment of the key staff. Currently the park offers 9,000 sq.m. labs and office space, and additional 100,000 sq.m. industrial property ready for expansion. The park is part of an international and regional network to assure access regional and to funding sources and cooperation with universities and hospitals. Co:bios Technologiezentrum Service for all stages of growth and expansion co:bios Technologiezentrum GmbH Neuendorfstraße 20 a 16761 Hennigsdorf Phone +49 3302 2021250 Fax +49 3302 2021257 info@cobios-technologiezentrum.de www.cobios-technologiezentrum.de Located in the northwest of Berlin, the co:bios Technology Center in Hennigsdorf is the congested urban area in Berlin-Brandenburg of biotechnology and life science. In the last 15 years more than 30 companies with approximately 700 international employees have settled on this site. With our holistic approach combining settlement, development, construction and licensing issues to the point of traditional management consulting, and on the background of the high density of innovative, research-intensive and service-oriented companies on the co:bios biotechnology park Hennigsdorf we can initiate interesting synergy effects for your business model. Within this locational advantages the co:bios biotechnology park became a magnet for the international healthcare industry and the percentage of international settlements on this site is growing, for example from USA, South America, VAI and Asia. Campus Berlin-Buch Interaction of Research, Clinics and Companies On more than 10,000 sq.m. we offer service space for extension to clean rooms (class D/E/F), S1 labs, DI-water supply, compressed air supply, special gas supply, state of the art data communication, meeting rooms, conference hall and more. The building and central technique requirements also meet the fulfillments for S2 labs for GMP/ISO 9001 based production specifications. As a center of excellence for biotechnology and life science we have a selected portfolio of service and advice to young start-ups as well as medium sized companies, in aim to support them across all stages of company growth. For those companies who have outgrown their limited Robert-Rössle-Straße 10 13125 Berlin Phone +49 30 94892511 Fax +49 30 94893812 info@bbb-berlin.de www.bbb-berlin.de Contact: Dr. Andreas Mätzold Executive Manager Dr. Ulrich Scheller Executive Manager 36

BioTOP-Report Biotech Parks Berlin-Buch is the location of one of the largest biotechnology parks in Germany, with 31,000 square meters of scalable lab and office space for start-ups and maturing companies. Situated to the northeast of the city, the Berlin-Buch Campus is currently home to 56 companies, 41 of which are biotech companies; the rest provides support services. Berlin Adlershof Germany s leading Science- and Technology Park Beside the BiotechPark the Max Delbrück Center for Molecular Medicine, the Leibniz Institute for Molecular Pharmacology as well as clinical groups from the Charité University Hospital within the Experimental and Clinical Research Center are part of the Campus community. The Campus gives access to high-end technology platforms, state of the art infrastructure, interdisciplinary communication, projects and expertise in a wide range of items, especially in translational research. The BiotechPark at the Campus Berlin-Buch offers: Adlershof Zentren für Biotechnologie und Umwelt WISTA-MANAGEMENT GMBH Rudower Chaussee 17 12489 Berlin Phone +49 30 63922221 Fax +49 30 63922212 terytze@wista.de www.adlershof.de Contact: Heidrun Terytze Head of Center for Biotechnology and Environment kkimmediately available lab and office space kkexcellent research and clinical expertise on-site kktraining programs for personnel on spot kkan international community of like-minded people kkinterdisciplinary networks and platforms Berlin Adlershof focuses on photonics and optical technologies, material and microsystems technology, information and media technology, as well as biological, and environmental technology. There are currently 25 biotech companies in Adlershof occupying 18,200 sq.m. of lab and office space. The companies focus on: The BiotechPark including the Innovation and Incubation Center is managed by BBB Management GmbH Campus Berlin-Buch. Acting as a full-service company BBB s main tasks are the settlement, accompanying and support of Biotech businesses. kkbiotechnology products and procedures development kkpharmaceutics, medicine, and medicine technology kkanalytics kkenvironmental technology Technical Equipment comprises laboratories with a basic equipment: security-lockers, laboratory basins, work benches, vacuum supply, preliminary setup for supply of pure gases and compressed air, reconfiguration for further media and gases, central cooling, preliminary setup for cold water supply 37

BioTOP-Report Biotech Parks in rental areas, refitting of heat exchanger by the tenant possible. Adlershof. Science at Work. Science Park Potsdam-Golm Connecting Excellence The GO:IN Innovation Center offers young technology-based companies and entrepreneurs a range of office and laboratory spaces along with extensive services and optimal support for a successful market launch. Close proximity to the other players at Potsdam-Golm and the intensive networking of the different institutions and companies here offer perfect conditions for the development and exploitation of synergies. Standortmanagement Golm GmbH Am Mühlenberg 11 14476 Potsdam-Golm Phone +49 331 237351130 www.wissenschaftspark-potsdam.de www.goin-potsdam.de Contact: Friedrich W. Winskowski Managing Director Science Park Potsdam-Golm combines cutting-edge international research and the training of young scientists in a high-powered location in the immediate vicinity of the German capital Berlin. Alongside the Faculty of Science and the Human Sciences Faculty of the University of Potsdam, three Institutes of the Max Planck and two of the Fraunhofer Society as well as an innovation center with currently 22 companies operate in Brandenburg s largest science park. More than 2,500 people work at Potsdam-Golm and more than 9,000 students are pursuing their academic qualifications here. The pleasant and very family-friendly working environment on the edge of a nature conservation area, the high quality of life in and around Potsdam and continuous growth make Potsdam-Golm a highly attractive location. Professional site management is extending the park infrastructure and fosters the integration of the capabilities and interests of all institutions, associations and companies that operate at Science Park Potsdam-Golm. 38

BioTOP-Report Addresses Addresses Addresses Networks 40 Biotech Parks 40 Other Parks 41 IP Asset Management 41 Universities and Research Centers 41 Banks and VCs 41 Supporting Organisations 42 Pharmaceutical Companies 42 Contract Manufacturers 44 Contract Research Organisations 44 Biotech Companies 46 For Companies on the Rise Equity Financing building on your strengths! Are you looking to expand your business and maximize on growth prospects in the technology sector in Germany? Yet, you require some support and equity financing to get your project successfully underway in a new marketplace? Then, we are the right partner for you! We pride ourselves in providing the best in equity financing to our 150 corporate clients totalling over 150 million in strategic financing. We are dedicated to assisting our customers to advance their businesses in new areas and to enable sustainable growth of business and even greater success. Remember, your success is our success. Let us be part of your success story! Contact us now. Foto: ILB www.ilb.de

BioTOP-Report Addresses Networks BioHyTec Verein für Bioanalytik und Biohybrid-Technologien e. V. BioResponseNetzwerk DiagnostikNet-BB Netzwerk Diagnostik Berlin-Brandenburg Health Capital Berlin- Brandenburg Regenerative Medicine Initiative Berlin-Brandenburg RiNA -Netzwerk RNA- Technologien Zentrum für Molekulare Diagnostik und Bioanalytik BioHyTec is the biohybrid technology network in the life sciences cluster of Berlin-Brandenburg. This new field of technology is the interface between biosensor development and microsystems technology. Biohybrid systems open up new applications in pharmaceutical research, clinical diagnostics, food analysis and genetic engineering. BioResponse is an interdisciplinary research and development organisation with members from Brandenburg, Berlin and Saxony. It focuses on the development and marketing of multiplex assays for diagnostic antibody identification based on the proprietary BioResponse technology, which is comprised of fully automated image analysis of fluorescence-encoded microparticles and labelled cell structures. DiagnostikNet-BB is the Berlin-Brandenburg network for in vitro-diagnostics. Members include biotech companies as well research institutes and clinics. Main objectives of the network are: Development of system solutions, optimizing compatibility, close cooperation with leading clinicians and joint marketing. In order to develop the scientific and economic position of the region, the governments of the states of Berlin and Brandenburg have put the master plan Healthregion Berlin Brandenburg into effect. Its key to a continued success is a continued close interplay between research, development and education7vocational training with production, application and supply. All of these activities are integrated and coordinated through the Network Gesundheitswirtschaft Berlin Brandenburg under the brand of Health- Capital. The mission of the RMIB is to promote the Berlin-Brandenburg region as a center of excellence for Regenerative Medicine particularly for cell-based medical biotechnology. The RMIB promotes networking in the field and supports the further development of clinical studies and education programs. The initiative fosters the collaboration between universities, research institutes, companies (including SMEs) and organizations in the field of science and technology. The RNA-Network provides ongoing support and funding for the development of RNA technologies with the goal to commercialize the results. One main focus is the improvement and application of the RNA interference technology. Further projects develop RNA aptamers, cell-free protein biosynthesis systems and analyse the structure and function of RNA molecules. The RiNA RNA-Network encourages co-operation and information exchange between academy and industry. The Centre for Molecular Diagnostics and Bioanalytics (ZMDB) is a virtual centre operated under the auspices of the Fraunhofer Institute for Biomedical Technology and the Charité Universitätsmedizin Berlin in close cooperation with the region s company networks. The aim is to bring together regional expertise in basic research, technology development, clinical research and industrial cooperation initiatives to set up joint projects that will speed up the development of in vitro-diagnostics Made in Berlin-Brandenburg. biohytec.de bioresponse.de diagnostiknet-bb.de healthcapital.de rmib.de rna-network.com zmdb.de Biotech Parks berlinbiotechpark Biotech Campus Potsdam berlinbiotechpark is located on a 86,000 m² site in the very heart of Berlin, currently offering a total of approx. 57,000 m² of office, laboratory and production space, with a building potential for another 45,000 m² of rental area. Offering flexible growth potential, production-orientated media equipment and comprehensive industrial-specific services and infrastructure, berlinbiotechpark is particularly attractive for growing internationally orientated technology companies. Just a few minutes away from Potsdam s central railway station in the direction of Caputh, BIOTECH CAMPUS POTSDAM is located on the Hermannswerder peninsula in the river Havel. It is owned and operated by BIOTECH CAMPUS POTSDAM GmbH, a fully owned subsidiary of the Investment Bank of the State of Brandenburg. Biotechnologiepark Luckenwalde Located just 30 miles south of Berlin and 25 miles from Berlin-Brandenburg International Airport in the rural district of Teltow-Flaeming, the Biotechnology Park Luckenwalde is one of the most modern facilities of its kind in Germany. It is home to 35 companies with about 500 employees from Germany, USA, UK, Korea, and Israel. Co:bios Technologiezentrum GmbH Campus Berlin-Buch bbb Management GmbH Adlershof Zentren für Biotechnologie und Umwelt The co:bios Technology Center in Hennigsdorf offers affordable rental opportunities and a selected portfolio of services and advice to young start-ups as well as medium-sized companies. Therefore Hennigsdorf is a center of excellence for life sciences, especially in the field of red biotechnology and medical technology. Berlin-Buch is home to one of the largest biotechnology parks in Germany, with 26.000 square meters of scalable lab and office space for start-ups and maturing companies. Situated to the northeast of the city, the campus is currently home to 56 companies, 41 of which are biotech companies; the rest provide support services. Berlin Adlershof is one of the most successful high-tech locations in Germany with focus on Photonics and Optics, materials and microsystems and media, biotechnology, and environment. There are currently 25 biotech companies in Adlershof occupying 18,200 sq.m of lab and office space. berlinbiotechpark.de biotechcampus.de bio-luck.de cobiostechnologiezentrum.de bbb-berlin.de adlershof.de 40

BioTOP-Report Addresses Other Parks GO:IN Golm Innovationszentrum GmbH Innovationspark Wuhlheide Science Park Potsdam-Golm is one of the most innovative and promising locations in Brandenburg. In the GO:IN facility, innovative companies will find an excellent working environment where they will benefit from the synergy effects of the location and the specific equipment offered by its laboratories. The location provides a wide range of services and consulting, as well as integration into the existing regional networks. So far 140 companies have decided to locate at the Wuhlheide Innovation Park, where the creative environment and service-oriented management provide important stimuli with respect to product development and innovation. Our companies have attractive office accommodation, workshops, laboratories and service areas at their disposal. Furthermore, they also have the opportunity to acquire fully developed investment sites for the evolution of their company! The location stands for successful new businesses, growth and long-term perspectives. wissenschaftsparkpotsdam.de goin-potsdam.de ipw-berlin.de IP Asset Management Ascenion ZukunftsAgentur Brandenburg GmbH Brainshell Ascenion advises public life science research institutions, universities, hospitals, freelance inventors and companies in all aspects of intellectual property asset management. Brainshell is an independent consulting agency specializing in intellectual property services for businesses.brainshell manages and markets the patent portfolios of all colleges, universities, and research institutes in the State of Brandenburg. ascenion.de brainshell.de Universities and Research Centers BAM Federal Institute for Materials Research and Testing Berlin-Brandenburg Center for Regenerative Therapies (BCRT) BfR Federale Institute for Risk Assessment Brandenburg University of Technology Charité - Universitätsmedizin Berlin Deutsches Rheuma-Forschungszentrum Berlin Fraunhofer Institute for Applied Polymer Research (IAP) Fraunhofer Institute for Biomedical Engineering (IBMT) Freie Universität Berlin German Heart Instiute Berlin German Institute of Human Nutrition (DIfE) Humboldt-Universität zu Berlin htw Berlin University of Applied Sciences Institute of Biomaterial Sciences, Helmholtz-Zentrum Geesthacht (Teltow) Institute for the Reproduction of Farm Animals Schönow Inc. Lausitz University of Applied Sciences Leibniz-Institute for Agricultural Engineering Potsdam-Bornim (ATB) Leibniz-Institut für innovative Mikroelektronik Leibniz-Institut für Molekulare Pharmakologie (FMP) Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch Max Planck Institute for Infection Biology Max Planck Institute for Colloids and Interfaces Max Planck Institute for Molecular Genetics Max Planck Institute of Molecular Plant Physiology Robert Koch Institute (RKI) Technische Universität Berlin (TU) University of Applied Sciences Berlin University of Applied Sciences Wildau University of Potsdam bam.de b-crt.de bfr.bund.de tu-cottbus.de charite.de drfz.de iap.fraunhofer.de ibmt.fraunhofer.de fu-berlin.de dhzb.de dife.de hu-berlin.de htw-berlin.de hzg.de ifn-schoenow.de fh-lausitz.de atb-potsdam.de ihp-microelectronics.com fmp-berlin.de mdc-berlin.de mpiib-berlin.mpg.de mpikg.mpg.de molgen.mpg.de mpimp-golm.mpg.de rki.de tu-berlin.de beuth-hochschule.de tfh-wildau.de uni-potsdam.de Banks and VCs BC Brandenburg Capital GmbH Berliner Sparkasse-Kompetenzzentrum Gründungen und Unternehmensnachfolge Berliner Volksbank eg bc-capital.de lbb.de berliner-volksbank.de 41

BioTOP-Report Addresses Banks and VCs bmp Life Science AG Business Angels Club Berlin Commerzbank AG Creathor Venture Demeter Partners Deutsche Bank AG High-Tech Gründerfonds Management GmbH IBB Beteiligungsgesellschaft mbh Investitionsbank Berlin Investitionsbank des Landes Brandenburg KfW-Mittelstandsbank Peppermint Venture Partners GmbH Ventegis Capital AG XLHealth bmp.com bacb.de commerzbank.com creathor.de demeter-partners.com db.com high-tech-gruenderfonds.de ibb-bet.de ibb.de ilb.de kfw-mittelstandsbank.de peppermint-vp.de ventegis-capital.de xlhealth.de Supporting Organisations Berlin Partner für Wirtschaft und Technologie GmbH Support of international and domestic companies in all issues regarding locating to Berlin. berlin-partner.de Coaching Bonus Specific Coaching offers for innovative high tech companies. coachingbonus.de Investitionsbank Berlin (IBB) Investitionsbank des Landes Brandenburg Landesamt für Gesundheit und Soziales Berlin (LAGeSo) Technologie Stiftung Brandenburg Technologiestiftung Berlin ZAB Zukunftsagentur Brandenburg ZAK Zentrale Anlauf- und Koordinierungsstelle Senatsverwaltung für Wirtschaft, Technologie und Forschung Company financing and consultation on subsidies and processing grant applications in Berlin. Company financing and consultation on subsidies and processing grant applications in Brandenburg. One Stop Agency for all licensing and approvals, for questions concerning biomedicine, biotechnology and pharmaceuticals and for more general issues connected with health, disease control and public health in Berlin. The technology Foundation Brandenburg is dedicated to the advancement of science and research, especially in the field of innovative technologies. The Technology Foundation Berlin is a public private partnership in the German capital region to develop science and industry networks for technology transfer, joint projects, and regional innovation strategies. The Brandenburg Economic Development Board functions as a one-stop agency for all kinds of business support services. Helps you find your way through the Berlin administration. Supports complex urban development policy and investment projects. ibb.de ilb.de berlin.lageso.de ts-bb.de tsb-berlin.de zab-brandenburg.de berlin.de/sen/wirtschaft/zak Pharmaceutical Companies Advance Pharma GmbH ALPHAMADE GmbH AstraZeneca Bausch & Lomb Dr. Mann Pharma Bayer Pharma Aktiengesellschaft Contract manufacturer of solid drugs.galenic development and admissions, analytics and microbiology, coating and granulation (organic and aqueous), compacting, packaging. Customized formulations as medications: parenteral feeding, intradialytic parenteral feeding, omega-3 fatty acids, cytostatics. We are a global innovation-driven biopharmaceutical company specialising in the discovery, development, manufacturing and marketing of prescription medicines that make a meaningful difference in healthcare. We operate in over 100 countries and our medicines are used by millions of patients worldwide. AstraZeneca was formed on 6 April 1999 through the merger of Astra AB of Sweden and Zeneca Group PLC of the UK two companies with similar science-based cultures and a shared vision of the pharmaceutical industry. Bausch & Lomb is the eye health company dedicated to perfecting vision and enhancing life for consumers around the world. Core businesses include soft and rigid gas permeable contact lenses and lens care products, and ophthalmic surgical and pharmaceutical products. Bayer Pharma is one of the ten largest specialty pharmaceutical companies in the world and the company's goal is a leading market position in each of its specialist fields. With its distinctive expertise in research, the company develops new medicines and therapies which make an essential contribution toward improving patient's quality of life. advance-pharma.eu alphamade.de astrazeneca.com bausch-lomb.de bayerhealthcare.com 42

BioTOP-Report Addresses Pharmaceutical Companies BERLIN-CHEMIE Aktiengesellschaft Chemisch-pharmazeutisches Labor, Rolf Sachse GmbH Daiichi Sankyo Dr. Kade Pharmazeutische Fabrik GmbH Haupt Pharma AG Heyl chemisch pharmazeutische Fabrik GmbH & Co. KG Klosterfrau Berlin GmbH medphano Arzneimittel GmbH MUCOS Pharma GmbH & Co.KG Pfizer Pharma GmbH Pharma Action GmbH PharmaMar GmbH Piramal Imaging GmbH Sanofi-Aventis Deutschland GmbH Shire Deutschland GmbH BERLIN-CHEMIE is a German subsidiary of the MENARINI Group. The company, which was formed in 1886 and is headquartered in Florence, was developed over the generations to become a global, owner-managed pharmaceutical company. Research is centred on the development of innovative drugs for the following areas: inflammatory diseases and pain, cardiovascular diseases, oncology, viral disease. CPL S: Custom synthesis development of active pharmaceutical ingredients (API s), Contract manufacture of active pharmaceutical ingredients from laboratory to kiloscale, Pharmaceutical analysis. Daiichi Sankyo is a global pharmaceutical company with corporate origins in Japan. We provide innovative products and services in more than 50 countries around the world. With more than 100 years of scientific expertise, our company draws upon a rich legacy of innovation and a robust pipeline of promising new medicines to help patients. Through the outstanding knowledge and commitment of our 30,000 employees worldwide, we create innovative new and generic medicines, and new methods of drug discovery and delivery. We share a passion for innovation, as well as compassion for the patients around the world who are in need of our medicines. The company s activities concentrate on the production and marketing of drugs in the fields of gynecology, proctology, pain relief/ rheumatism and urology. The potential of proven drugs is expanded systematically by galenic developments to produce innovative products. With&nbsp,nine production sites Haupt Pharma is one of the leading contract manufacturers for pharmaceutical products in&nbsp,the world&nbsp,today.&nbsp,about 2.000&nbsp,employees produce for an established clientele of more than 200 important international pharmaceutical companies, amongst which 15 of the international TOP 25. HEYL is an independent, entrepreneurial family business that has its headquarters in probably the liveliest German metropolis, Berlin, since its establishment in 1926. In cooperation with our international subsidiaries, the main focuses of our work are the Regulatory Affairs and marketing of medicines as well as the sale of active pharmaceutical ingredients (API's) and special chemicals. For more than 175 years Klosterfrau has been developing, manufacturing and marketing pharmaceutical products. The profile of traditional yet modern natural medicines has grown significantly in recent times. Based on the latest scientific discoveries combined with the development of new markets, the range is constantly being expanded with innovative products. medphano Arzneimittel in Rüdersdorf stands for proven and cost-effective pharmaceutical preparations. Main products are analgesics/anti-rheumatics, antibiotics, dermatics, diuretics, drugs to stimulate blood circulation, drugs for treatment of gastro-intestinal disorders, vitamins, expectorants, lipid-lowering agents, ophthalmics, cosmetics, food supplements, diet foods and foods. As a specialist in enzyme preparations Mucos supplies a steadily growing market with specific and variably dosed enzyme combinations. The company leads the world market in oral enzymes for therapeutic purposes. Pfizer is the world's largest research-based biomedical and pharmaceutical company. Pharma Action has extensive expertise in global pharmaceutical marketing and manufacturing since 1988 and offers cutting edge API solutions to the pharmaceutical industry in Europe and abroad. PharmaMar is a biopharmaceutical subsidiary of Grupo Zeltia; it is a world leader in discovering, developing and marketing marine-based drugs to treat cancer. Yondelis is the first marine-based antitumour drug. PharmaMar has four other compounds in clinical development: Aplidin, Zalypsis, PM01183 and PM060184. PharmaMar also has a rich pipeline of pre-clinical candidates and a major R&D programme. PharmaMar GmbH, the German subsidiary, was officially established in November 2013 in Berlin. Piramal Imaging is a start-up business within the Life-Science division of the Mumbai-based Piramal Enterprises Group. The company is dedicated to the clinical research & development and the global commercialization of Nuclear Medicine / Molecular Imaging products for detection, characterization and monitoring of disabling and life-threatening diseases in neurology, oncology and the cardio-vascular space. Sanofi-aventis is a leading global pharmaceutical company based in Paris and operating in over 100 countries. R&amp,D teams work on a global approach to patients, offering innovative therapeutic strategies in thrombosis, cardiovascular diseases, diabetes, vaccines, oncology, the central nervous system disorders and internal medicine. Shire s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder, human genetic therapies and gastrointestinal diseases. berlin-chemie.de cpl-sachse.de daiichisankyo.com kade.de haupt-pharma.de heyl-berlin.com klosterfrau.de medphano.de mucos.de pfizer.de pharma-action.com pharmamar.com imaging.piramalenterprises. com sanofi-aventis.de shire.de 43

BioTOP-Report Addresses Pharmaceutical Companies Spreewälder Arzneimittel GmbH Steiner & Co. Deutsche Arzneimittelgesellschaft mbh & Co. KG Steripharm Pharmazeutische Produkte GmbH & Co. KG Takeda GmbH Teva GmbH Spreewälder Arzneimittel is a contract manufacturer of drugs, veterinary drugs, food supplements, diet foods and cosmetics in liquid, semi-solid and solid administration forms. Production and marketing of pharmacy and prescription drugs, particularly plantbased drugs (tranquillizers, rheumatism drugs, bile duct and gastro-intestinal as well as gynecological and urological drugs), analgesics and mineral preparations. Production and marketing of folic acid products. Takeda is Japan s and Asia s largest pharmaceutical company and among the leading global companies of its branch, represented in more than 70 countries. Takeda committed itself for a better health care of patients all over the world by innovations in medicine. Its therapeutical core areas are metabolic, cardiovascular, inflammatory, immune and respiratory diseases, diseases of the central nervous system, oncology, gastroenterology and pain. Teva in Germany is the leader in generics and an expert in innovative brand business. The German headquarter is located in Ulm. Patent-protected medicines from the fields of neurology, oncology, pain management and respiratory diseases are marketed by Teva Specialty Medicines in Berlin. Teva Specialty Medicines primary area of success is neurology. The first product to be come from the company's own development facility contains the active ingredient glatirameracetate and is the market leader among drugs used to treat multiple sclerosis. Another product from Teva s own research laboratories, is a standard in the treatment of Parkinson s disease. spreewaelder-arzneimittel.de steinerarznei-berlin.de steripharm.de takeda.de teva.de Contract Manufacturers Advance Pharma GmbH ALPHAMADE GmbH Ayanda GmbH & Co. KG Chemisch-pharmazeutisches Labor, Rolf Sachse GmbH Haupt Pharma AG Pharma Action GmbH Spreewälder Arzneimittel GmbH Contract manufacturer of solid drugs.galenic development and admissions, analytics and microbiology, coating and granulation (organic and aqueous), compacting, packaging. Customized formulations as medications: parenteral feeding, intradialytic parenteral feeding, omega-3 fatty acids, cytostatics. Ayanda is an innovative business partner and manufacturer of consumer ready pharmaceuticals and food supplements. In Pritzwalk, Brandenburg, the company has a pharmaceutical soft gel encapsulation plant. CPL SACHSE offers: Custom synthesis development of active pharmaceutical ingredients (API s); Contract manufacture of active pharmaceutical ingredients from laboratory to kiloscale; Pharmaceutical analysis. With nine production sites Haupt Pharma is one of the leading contract manufacturers for pharmaceutical products in the world today. About 2.000 employees produce for an established clientele of more than 200 important international pharmaceutical companies, amongst which 15 of the international TOP 25. Pharma Action has extensive expertise in global pharmaceutical marketing and manufacturing since 1988 and offers cutting edge API solutions to the pharmaceutical industry in Europe and abroad. Spreewälder Arzneimittel is a contract manufacturer of drugs, veterinary drugs, food supplements, diet foods and cosmetics in liquid, semi-solid and solid administration forms. advance-pharma-berlin.de alphamade.de ayanda.com cpl-sachse.de haupt-pharma.de Pharma-action.com spreewaelder-arzneimittel. de Contract Research Organisations analyze & realize ag Allied Clinical Management GmbH Assign International GmbH BLS Preclinical Services analyze & realize ag is a leading CRO and consulting firm, which primarily give complete advice and guidance to companies in the natural products sector. The CRO has broad experience in monitoring and managing phase I to phase IV clinical trials including advanced therapy medicinal product (ATMP) trials as well as in accompanying and conducting medical device trials and post-marketing surveillance. Assign International in Berlin is part of the Assign Group, a mid-sized full-service CRO with six offices in five countries.our expertise meets development requirements of pharmaceutical and biotechnological industries. We manage clinical trials from study set-up to final clinical report.our services, among others, comprise Data Management and Biostatistics, integrated EDC-Systems, Pharmacovigilance, Protocol Writing, Laboratory Services and Quality Management. BLS Preclinical Services is a contract research organization (CRO) located in Berlin. BLS provides a range of highquality and integrated preclinical services in animal models. Through our highly skilled scientific partners we provide a one-stop service and tailored solution. We take the time to understand your business needs and provide comprehensive tailored solutions either in-house or in co-operation of our network. We are backed by a highly skilled scientific team with a wealth of experience in all disciplines of preclinical development. analyze-realize.com allied-clinical.com assigngroup.com bls-germany.com 44

BioTOP-Report Addresses Contract Research Organisations CBR Biotech Strategies GmbH Charité Research Organisation GmbH Cooperative Clinical Drug Research and Development (CCDRD) AG CSG Clinische Studien Gesellschaft mbh Dr. Notghi Contract Research Klinische Forschung Berlin GbR Klinische Forschung Gruppe Nord GmbH Lampe & Company GmbH & Co. KG MEDIS RESEARCH GROUP OSMUNDA Medical Device Service Group PAREXEL International GmbH PharmaLex GmbH Sacura GmbH WITEGA Laboratorien Berlin- Adlershof GmbH CBR International Corporation is a global, full-service product, clinical, and regulatory compliance development group dedicated to providing comprehensive consulting services. We understand commercial pressures and regulatory constraints of biopharmaceutical product development and offer full support and guidance to all of our clients. Our experienced staff and consulting affiliates offer detailed and strategic services to members of the biotechnology, pharmaceutical, and device industries worldwide. Based in Berlin, the Charité Research Organisation (CRO) was founded in collaboration with Berlin s famous Charité University Hospital. This relationship fosters a level of cooperation with centers of clinical excellence that we think is unique in the industry. The CRO offers a whole new approach to the concept of partnering with centers of clinical excellence to facilitate access to patients, clinical expertise and specialist methodologies in support of early clinical development programs. CCDRD is an independent contract research organization (CRO). CCRDR is dedicated to offer creative and innoative full service from planning to market authorization to its customers in the pharmaceutical, biotechnological and medical device industry. Since its foundation in 1998, the CSG Clinische Studien Gesellschaft mbh has focussed on aligning clinical research with public health demands, with special attention to facilitating access by physicians and patients to clinical studies.csg cooperates closely with the largest research institute for public health in Germany, the IGES Institut. Dr. Notghi Contract Research GmbH is a service provider for large, medium and smallsized companies in the pharmaceutical, generics and biotechnology industries. We support and advise you in the conduct and management of national and international projects. Klinische Forschung Berlin is a study centre that implements clinical studies from phases IIA to IV for the pharmaceuticals industry. The Klinische Forschung Gruppe Nord (Clinical Research Group North) is a network of independent investigator institutes with five centres in Northern Germany, two of them in Berlin.The Klinische Forschung Gruppe Nord has carried out trials with up to 250 patients. Phase II and III studies are the core competence. The test centres have altogether 30 overnight accommodation places for phase I and IIa studies. Lampe & Company is a consulting firm specialized in multidimensional analysis of biomedical literature for evidence-based decision making. Our team of experts combines industry expertise with our unique L-Matrix Method and exclusive L&C relational database to deliver critical information to leading decision makers of pharmaceutical, life sciences, and medtech companies. MEDIS RESEARCH GROUP is a partnership of clinical research services providers with a joint mission to combine clinical research expertise and provide complete service solutions across all stages of the clinical development process. OSMUNDA is the largest Chinese clinical trial CRO and service provider for the medical device and in-vitro diagnostic industry. Over 2000 international clients have entrusted our expertise in regulatory affairs, clinical trials and industrial distributor/supplier resources to achieve their business goals. The German subsidiary of the US clinical research organization PAREXEL employs more than 1,400 people in Berlin. In two units with a 160-bed capacity (incl. 8 sleep lab beds) and an annual enrollment of approximately 2,500 volunteers in Berlin, more than 75 clinical studies are performed each year. PharmaLex is one of the leading service providers in the International pharmaceutical business. The company is dedicated to the development, registration and marketing authorization, market access and product maintenance of medicinal / biotechnological products and medical devices, worldwide. The corner stones of PharmaLex successful co-operation with companies of all sizes and specializations are very high quality of work, reliability, efficacy, flexibility and anticipatory strategic planning. Sacura is a full-service contract research organization granting a high level of quality (FDA approved), flexible structures and qualified staff. WITEGA Laboratorien Berlin-Adlershof GmbH is a medium-sized company specializing in the realization of organic customer syntheses. Our customers are companies from the chemical and pharmaceutical industries as well as from other technology fields. The main focus of our activities is the lab-scale custom synthesis of organic building blocks, intermediates and target structures and of isotope-labeled compounds (D, 13C, 15N) for chemical and pharmaceutical research and development. The company is also a supplier of analytical standards for residue analysis (especially in veterinary medicine). cbrintl.com charite-research.org ccdrdag.com csg-germany.com notghi.com klinische-forschung-berlin. de kfgn.de lampeandcompany.com medis-research.com osmundagroup.com parexel.com pharmalex.com sacura-cro.com auftragssynthese.com 45

BioTOP-Report Addresses Biotech Companies 3B Pharmaceuticals GmbH 8sens.biognostic GmbH ABiTEP GmbH Accelero Bioanalytics GmbH Acuros GMBH 3B Pharmaceuticals GmbH (3BP) is a privately held pharmaceutical R&D company based in Berlin, Germany. The company is dedicated to the development of peptide-based pharmaceutical and diagnostic products. 3BP is pursuing projects in hemophilia and nuclear medicine. 8sens.biognostic develops, produces and sells rapid tests (lateral-flow) and ELISAs for different markets (human and veterinary diagnostics, food control). Our products are the QuickSens -tests for h-fabp, TropI, CRP and hs-crp and the Reader for quantification QuickSens OMEGA. Development-on-demand, feasibility studies and production-on-demand are also offered. The ABiTEP GmbH is working in development and production of biotechnological products for sustainable agriculture. The team of ABiTEP works for development of non GMO customer specific technologies in laboratory scale and scale up with modern equipment and Know how. Capacities for fermentation up to 5.000 L, down stream equipment as well as freeze drier with capacity of 90 L are available for services. A molecular biology lab is available for basic science. Accelero Bioanalytics GmbH is a biotech CRO focussing on GxP compliant bioanalytical ligand binding assays. The company supports PK and PD preclinical/ clinical drug development on microrna, mirna, sirna, aptamers, plasmid APIs, antisense drugs, as well as peptide hormones, biosimilars, antibody therapeutics, or cell-based therapeutics (ATMP). The Applied Biosystems Viia7 real-time qpcr system with IVD label for human Dx operates in full compliance to Good Laboratory Practice (GLP). Development of osmotic micropumps for medical or microfluidic applications.the innovative technology enables new options in liquid handling from disposable micropumps for drug delivery to precision micropumps for lab-on-a-chip development. 3b-pharma.com biognostic.de abitep.de accelero-bioanalytics.com acuros.de Adrenomed AG Development of biologics against severe sepsis. adrenomed.com Aevotis GmbH AFOSA GmbH Aglycon Mycoton GmbH AJ Innuscreen GmbH Alacris Theranostics GmbH Alcat Europe GmbH Algenol Biofuels Germany GmbH ALRISE Biosystems GmbH Amal Therapeutics S.A. Amocol Bioprocedures Ltd. AnaKat Institut für Biotechnologie GmbH The core competencies of aevotis lie in the targeted conversion of simple carbohydrate containing substrates (e.g. agricultural by-products, waste streams, inexpensive sugars) to high-value carbohydrate based products, their characterization, processing and testing. Marketable products include novel /optimized enzymes, expression systems,&nbsp, specialized biotransformation and down-stream processes, customized oligomers and polymers for food and non-food uses. Development, production and marketing of diagnostics (ELISA kits), primarily for use in veterinary medicine. Aglycon Mycoton GmbH is active in the research, development and application of biopolymers as well and their manufacture and the sales and marketing of products based on these. The AJ Innuscreen GmbH is a young life science company working in the field of biotechnology and boosts the life science unit of Analytik Jena AG. Innovative technologies and products are developed and produced for the isolation and purification of nucleic acids. Reagent systems for molecular biology, as well as technologies and products for molecular diagnostics, are also included in the product portfolio. The company is EN ISO 9001:2008 and EN ISO 13485:2003 + AC:2009 certified. Alacris Theranostics GmbH is a company based in Berlin specialised in developing new approaches in personalised medicine for cancer patient diagnosis, treatment and drug stratification. Alacris is applying a systems biology approach that has been developed in the Department of Prof. Lehrach at the Max Planck Institute for molecular Genetics and is exclusively licensed as ModCellTM to Alacris. Alcat Europe GmbH is the daughter of the US company Cell Science Systems, the original developer of the Alcat test technology. The company is specialized to identify intolerant reactions of the leucocytes to foreign substances like foods, drugs or chemicals. The company focuses on the biotechnological use of cyanobacteria, especially the development and optimization of cyanobacteria for the production of environmentally friendly biofuels and chemical feedstocks. ALRISE is a drug delivery company that specializes in the nano- and micro-encapsulation of active ingredients. Using its globally patented ImSus technology, ALRISE are developing parenteral deposit pharmaceutical forms for proteins, peptides or small molecules. Customers are mainly large pharmaceutical companies who are developing improved administration forms for active ingredients whose patents are expiring together with ALRISE as part of their Product Lifecycle Management. Amal Therapeutics SA is a Swiss biotech start-up company and spin-off from the University of Geneva with a subsidy in Berlin. Amal uses its proprietary cell penetrating peptide platform to develop and progress therapeutic vaccines in oncology. Amocol Bioprocedures Ltd is a life science research & development and manufacturing company headquartered in Germany. Our mission is to supply innovative affinity chromatography media products and protein purification tools for research scientists and clinical customers in public sector institutes and industry. AnaKat Institut für Biotechnologie GmbH has specialized on analytical determination of pharmaceutical ingredients. aevotis.com afosa.com aglycon-mycoton.net aj-innuscreen.de alacris.de alcat-europe.com algenol.com alrise.de amaltherapeutics.com amocol.com anakat.de 46

BioTOP-Report Addresses Biotech Companies Analyticon Discovery GmbH Analytisches Zentrum Biopharm Berlin GmbH AnaTox GmbH & Co. KG Anau Berlin-lab GmbH ANiMOX GmbH Aokin AG ARGUS Umweltbiotechnologie GmbH Artemiflow GmbH ASCA GmbH Angewandte Synthesechemie Adlershof Astra Biotech GmbH ATLAS Biolabs GmbH Attomol GmbH Molekulare Diagnostika AudioCure Pharma GmbH AutoTissue GmbH Avitop GmbH AnalytiCon is a biotechnology company focusing on the development of compound libraries consisting of natural product (NP) and synthetic small molecules. As the global market leader in NP small molecule screening compounds, AnalytiCon is the only company which is able to provide vast collections with completely disclosed structural information. As a pure compound provider the company is offering its products and services to the pharmac., chemical, biotech, cosmetical and nutraceutical industry. Analytisches Zentrum Biopharm GmbH Berlin is a contract research organization providing services on pharmaceutical analysis and bioanalysis for active compounds in the dosage form, for the quantitative determination of analytes in a biological matrix and also the determination of physicochemical parameters of chemicals according to OECD guidelines. AZB carries out these services in compliance with GLP and GMP and has the GLP certificate. The AnaTox GmbH & Co. KG deals with the development and optimization of analytical methods and devices for HPLC and dissolution. Development and distribution of lab devices. Development of applications for the use of natural peptide / amino acid mixtures in chemistry and biotechnology, f.i. as a scavenger material in formaldehyde bounded formulations, foaming or hydrophobic Tensid compounds or as a N-source in biotechnological fermentation processes, distribution of a technology for the production of such basic materials from raw and residual materials. Aokin AG is a Berlin biotechnology company that is specialized in the development and commercialization of innovative analytical systems on the base of the rapid kinetic assay technology. The aokin systems are unique in their precision and operating speed. Areas of application are food and antibody analytics as well as clinical diagnostics. We also offer laboratory services in the area of food analytics, Pharmacoanalytics and chemical synthesis. ARGUS is a medium-sized company. Since 1987 ARGUS works on the field of remediation of contaminated groundwater, soil, waste water and waste air. ARGUS is able to elaborate a specific remediation program in each different pollution case considering economic aspects beside ecological aspects. All necessary treatment steps can be planned and carried out. The combination of microbiological steps with classic processes leads to a successful remediation of complex contamination. Artemiflow is a spin-off from the Max Planck Institute of Colloids and Interfaces (MPIKG). By the industrial use of an international patent held by MPIKG, Artemiflow uses a new process to produce Artemisinin from dihydroartemisinic acid (DHAA). DHAA is available in abundance in the waste of the current production process for Artemisinin. ASCA is a partner for contract research in the field of medicinal chemistry. The synthesis and optimization of lead structures, the development of new active structures and their check on a laboratory scale are offered. We take a lot of care on working out the synthetic schemes, rapid preparations and exact analysis of the samples. All our results are carefully documented for our customers. Access to literature databases and in-house analytical facilities are available. Astra Biotech GmbH offers high quality reagents, allergens, antibodies, recombinant proteins, and assays for the determination of hormones, allergies, tumour markers and infectious diseases. Quality is one of the key cornerstones on which Astra Biotech maintains its reputation and with which we strive to increase customer satisfaction and gain growing customer loyalty. We take great pride in our highest quality assays, which are all IVD compliant and therefore suitable for direct, accurate and reproducible diagnostic purposes, as well as for research. ATLAS Biolabs GmbH is a leading provider of microarray based genomic services such as genome wide gene expression and SNP analysis, CGH analysis and diagnostic services for registered doctors and hospitals, as well as for pharmaceutical, biotechnological and diagnostic enterprises. The company s aim is to develop, produce and distribute medical diagnostics for human medicine in the field of molecular genetics, infectious and autoimmune diseases. AudioCure is focus on the clinical development of drug candidates for neurodegenerative diseases with high unmet medical need. The company is engaged in the development, production and marketing of medical devices for cardiovascular surgeons. The products are specially made for the patients and have less side effects. The first certified product was a pulmonary heart valve (Matrix P) for the right ventricular outflow tract reconstruction (RVOT). The second product is also a heart valve which considerably shortens the operation time (Matrix P plus). Meanwhile a complete glutaraldehyde free valve is available called Matrix P plus N. Avitop is focusing on probiotics and food concepts with specific health indications. Based on the highest scientific standards, we develop a new generation of probiotics and food with unmet specific functions.we deliver the food industry with new and specific solutions for actual and future health challenges facing modern society. ac-discovery.com analytisches-zentrumbiopharm.de anatox.de animox.de aokin.com argus-umwelt.de artemiflow.com asca-berlin.de astrabiotech.de atlas-biolabs.com attomol.de audiocure.de autotissue.de avitop.de 47

BioTOP-Report Addresses Biotech Companies Bbi-biotech GmbH BEB BioEnergy Berlin GmbH BG Berlin-Genetics GmbH Bioanalyt GmbH Bioassays GmbH Biochrom AG BIOCYC Gesellschaft für Biotechnologie und Recycling mbh & Co.KG BioGenes GmbH Bioline GmbH BioMedion GmbH Biopract GmbH Biorefinery.de GmbH BioRepro GmbH BioS Biotechnologie Schönow GmbH BioSilta Europe GmbH BIOSYNTAN Gesellschaft für bioorganische Synthese mbh In the focus of the activities of bbi-biotech lie systems for the sterile sampling from bioreactors for all applications in the biotechnology, pharmaceutical, food, cosmetics and chemical industry. In addition, bbi-biotech develops components - in especially disposable ones - for the preparation of a new generation of fermentors and bioreactors and offers consulting and planning services for biotech projects, its implementation and services. Planning, Design, Construction, Supervision and Implementation of Biogas/Hydropower plants, Preplanning, Feasibility Studies and Research activities in the field of renewable energies, Optimization of the process in existing biogas plants. BG Berlin-Genetics GmbH is a new provider for genetic diagnostics and consulting in genetic diagnostics. We are a team of experienced human geneticists and have worked for many years in the field of human genetic science and human genetic diagnostics. Our aim is the development of innovative cooperation concepts, to connect classical patient-based medical care centers with modern technology-based service centers. In future, these cooperation forms will enable efficient, high quality, and patient-based genetic diagnostics. Bioanalyt develops and distributes the worldwide first easy-to-use and portable test kits for the analysis of vitamins and micro nutrients. The icheck-iex test kits enable food producers, food authorities and NGOs to monitor their ongling food programms more efficiently and at low-cost. The company was founded in 2006 by Prof. Dr. F. J. Schweigert as a spin-off of the University of Potsdam. Read more on our website bioanalyt.com. Service related to the development of medical in vitro-diagnostic products. Basic science to clinical development. Profiling of biomarkers in clinical trials. Biochrom is Germany s largest manufacturer of cell culture products (media, sera, and others) and sterile liquids. They are distributed to universities, industrial cell culture laboratories and industrial manufacturers. Service is of special significance for users of cell cultures. Special media developments and production optimizations are offered. Production of bio-chemicals, peptides, in vitro-diagnostics, test-kits. Development of consumer service for peptides and biochemicals. BioGenes is a full service immunoassay and antibody (monoclonal and polyclonal) development company with outstanding problem solving capabilities specializing in challenging projects that are carried out by an exceptionally experienced and interdisciplinary team. Our mission is to provide customers with a range of products which are fast and easy to use, guaranteed to work and developed by scientists who understand what our customers are trying to achieve so they can focus on their scientific goals. Bioline reagents are used by molecular biologists and other research scientists to perform test-assays and research in many fields from medical, biotechnology and marine biology. IT-Service for all GxP-Regulatory Tasks Data- and Document Management, Long-Term- Archiving and Digital Signature, SOP-Management, CAPA, Raw Data Management, Consulting for Validation of Computerized Systems according to GAMP4/5. Service and Additives (enzymes, trace elements, microbes) for biogas and waste water sludge treatmentenzyme analysis in agriculture industry Contract reserach feed additives. Based on main precursors of plants, carbohydrates in kind of sugar, starch and cellulose, and proteins, the biorefinery.de company has developed four complex product lines (Biorefinery systems) which leads to a great number of valuable products with the help of chemistry and biotechnology. BioRepro is the first pharmac. company, whose core competency is the breeding of leeches under controlled laboratory conditions for medical therapies. We concentrate on the establishment of GMP breeding procedures and will be able to provide leeches with standardized quality while equally allowing scalability to supply medical demand. Additionally, through the re-initiation of fundamental research, we will gain deeper understanding of further potential in medical and cosmetic treatment areas. Embryo transfer and associated biotechnologies in animals. Service, training and research in this field. BioSilta is an international company that specializes in advanced tools for microbial cell cultivation, protein production, enzyme screening and food spoilage testing. The patented EnBase technology resembles fed-batch mode and provides a cultivation environment with glucose-control, ph maintenance and inhibition of growth-limiting metabolites without the need for traditional mechanical pumps. EnBase is provided in ready-to-use liquid or tablet products. BioSilta specializes in small-scale cultures and it?s products offer customer solutions from multi-well plates to small-scale bioreactors. Learn more about our products and applications at biosilta.com. BIOSYNTAN offers the custom synthesis of standard peptides, the synthesis of modified peptides (e.g. glyco- and phosphopeptides, dye labeled peptides) and hapten modifications for the conjugate synthesis. In cooperation with BIOGENES GmbH Berlin we offer poly- and monoclonal antibodies. bbi-biotech.com bebgmbh.de bg-berlin-genetics.de bioanalyt.com bioassay-online.de biochrom.de quartett.com biogenes.de bioline.com biomedion.com dsmbiogas.com biorefinery.de biorepro.de bios-schoenow.de biosilta.com biosyntan.de 48

BioTOP-Report Addresses Biotech Companies Biotech-Laboratorium für Environment BLE GmbH biotechrabbit GmbH BIOTECON Diagnostics GmbH BioTeZ Berlin-Buch GmbH BIOWORX -Biotechnologielabor- Thomas Grimm BiRDS Pharma GmbH Blue Biolabs GmbH Botiss medical AG BST Bio Sensor Technology GmbH Caprotec bioanalytics GmbH Capsulution Pharma AG Celares GmbH Cell Medica GmbH Development of detection systems which are able, economically and rapidaly, to detect oil contaminations and industrial oil waste, in soil and in water and their biological depletion. The BLE GmbH is concerned with the biological degradation of oil contaminations and the development of a set of bio-preparations consisting of different bacterial strains which break down oil. biotechrabbit GmbH is determined to offer the newest and best life science products and innovative solutions to scientists leading the fight againstdisease and fueling our lives with innovations. We supply ultra pure enzymes and high-quality antibody services for diagnostics and a life science product portfolio(including reagents for PCR and nucleic acid purification)for molecular biology and proteomics. The biotechrabbit advantage is our combination ofpassion for excellent research with the agility of true entrepreneurship. BIOTECON Diagnostics has been well known as a qualified partner in the field of molecular and microbiology for the last 13 years. We focus on development, production and marketing of PCR-based rapid detection systems. BIOTECON Diagnostics offers solutions for the food and beverage industry as well as for producers of pharmaceuticals and cosmetics. Services (Custom DNA and RNA Oligonucleotide synthesis, Immuno affinity columns) - Development of Enzyme Immunoassays, e.g. for Therapeutic Antibodies- Bio Conjugates - Immobilization of Bio Molekules for better Signalling-R&D (Aptamer). BIOWORX offers services in the fields of contract research for customer-specific Biotransformations, the screening, isolation and production of Biocatalysts from microorganisms and plants and the bioanalytic syntheses. Further organic compounds and metabolites will be synthesized with enzymes for customer in kg scale. BiRDS Pharma GmbH, integrated into the BDD/CCDRD group, provides services in the field of drug development to pharmaceutical and biotech companies, including management of drug development projects as well as consulting services. The company also pursues own drug development projects based on intellectual property generated within BDD/CCDRD group, with a focus on drug candidates derived from Atomic Substitution Technology (AST). Blue Biolabs is a spin-off company from the TU-Berlin, which specialises in the development of products and services in the field of environmental analysis using methods of microbiology and molecular biology. Botiss biomaterials is a privately owned biotech company, headquartered in Berlin. botiss is the leading German specialist for dental bone and tissue regeneration (BTR). We focus on the development of innovative regenerative materials and clinical marketing / distribution in over 50 countries world-wide. The botiss subsidiary Cell+Tissue Bank Austria is a leading European manufacturer of allogenic materials for hard tissue regeneration. BST develops and produces biosensors to provide high quality analysis at moderate prices. In 1982 BST brought on the market the first multi-way biosensor based blood glucose analyzer in Europe and is since then market leader in Europe. Today BST sells more than 60.000 sensors a year. Since 2008 BST is besides biosensors also manufacturer of POCT and laboratory instruments. Caprotecs Capture Compound Mass Spectrometry (CCMS) Technology allows separation and isolation of proteins based on functionality. For many applications, CCMS is clearly superior to conventional methods - thus addressing an unmet need in the proteomics research community. The company is commercializing the CCMS technology through ImproMed projects with pharmaceutical and biotechnology companies. The focus on these collaborations is on investigating mechanisms of drug action (MoA) and identification of on- and off-target proteins to understand potential adverse effects of drug candidates on a molecular level. This can be easily carried out in the lead optimization process, or even earlier to increase the probability of success later on in the clinic. Capsulution Pharma AG develops innovative nano- and micron-sized capsules. The company applies its worldwide-patented so-called LBL-Technology. Based on their minute size, their functionality and their highly reproducible production process the capsules can be used for a multitude of different applications. Accordingly, the precisely sized capsules (500 nm to 50 µm) can be made to function in a manner to suit the intended application, and can be given the appropriate biochemical, electrical, optical and magnetic properties as required by the customer. Specialist for Drug Delivery of peptides/proteins by using PEGylation. Modification of Biopharmaceuticals with polyethylene glycol in order to substantially improve pharmacological properties. Offers the unique CelaSYS-PEGylation technology, which is patented by celares. CelaSYS: non-dispersed, highly branched polyethylene glycol based reagents. Additionally celares offers customized PEGylation solutions as well as synthesis of customized PEG-reagents. Cell Medica develops, manufactures and markets personalized cellular immunotherapeutics for infectious disease and cancer. mobiclup.de biotechrabbit.com bc-diagnostics.com biotez.de bioworx.de birdspharma.com bluebiolabs.de botiss.com bst-biosensor.de caprotec.com capsulution.com celares.com cellmedica.co.uk 49

BioTOP-Report Addresses Biotech Companies CellServe GmbH CellTrend GmbH Chemicell GmbH Chipron GmbH CHIRACON GmbH CMZ-Assay GmbH co.don AG CONGEN Biotechnologie GmbH Cyano Biotech GmbH DendroPharm GmbH DexLeChem GmbH Diaglobal GmbH DIZG Deutsches Institut für Zell- und Gewebeersatz gemeinnützige GmbH Dr. Götz Verfahrenstechnik Biotechnik Umwelttechnik Dr. Lerche KG Dr. Otto GmbH Dr. Rölleke Labor für Genetische Analytik GmbH CellServe is a service provider for research groups in regenerative medicine and fills an important gap in the conversion of applied treatment concepts from research into marketable products. Furthermore CellServe develops own innovative cell-based products for cardiology and uses novel cardiac derived cells ("From the Heart to the Heart") for the treatment of chronic heart failure. Celltrend is certified according to ISO 9001, ISO 13485 and GMP Cell culture systems for research on active substances (bioassays, preclinical research, for quality control) Development and production of antibody-based detection systems (ELISA) Chemosensitivityassay for optimisation of chemotherapy (tumor patients). Chemicell develops and produces magnetic, fluorescent and coloured nano- and microparticles, reactive fluorescent dyes and special chromatography-materials for the separation or detection of cells, bacteria, viruses, proteins or DNA/RNA and new gene transfer systems. Chipron GmbH specializes in production and distribution of array based detection systems for DNA/pathogens. chiracon is a qualified partner to develop chiral intermediates at a constant high quality for innovative drugs regarding economic, environmentally acceptable and scaleable aspects. We offer support through expert knowledge and key technology to meet your increasing needs. Our core competence is chirality. In addition we have a broad variety of chiral building blocks as an inhouse raw material source for high-level API production and development. Marketing of diagnostic reagents for measuring concentrations of proteins, hormones and their isoforms, exclusively for research purposes. co.don AG is one of the leading biopharmaceutical companies in the area of RegenerativeMedicine/Tissue Engineering. Since 1997, co.don AG has developed, manufactured anddistributed human Tissue engineering therapeutics for the regeneration of articular cartilage and intervertebral discs. CONGEN is specialized in food testing by molecular analytics based on DNA and RNA detection. CONGEN has been a pioneer for over a decade in the development and application of food and feed analytics by real-time PCR. The methods are available as complete analytic kit as well as a Service. Our mission is to serve the food industry with an excellent service and with standardized and reliable test kits in order to realize highest possible food safety and food quality. Cyano Biotech identifies and characterizes natural products from cyanobacteria and optimizes their pharmacological activities employing a biocombinatorial approach. The company conduct further development of identified lead structures till the preclinical phase. DendroPharm, a spin-off from the Free University of Berlin, develops innovative customized to drugs nanocarriers, which allow active pharmaceutical ingredients more focused and objective to bring: in tumor tissue, cartilage or into the skin. We are experts in the reactivation of complex chiral catalysts. For the first time the unmodified homogeneous catalyst can be re-used repeatedly thanks to our innovative water based process. Supported by quantum chemical analysis we are able to simulate catalytic cycles. Combined with our special knowhow this enables us to find the best solvent system for our customers. By using this new resource-efficient reaction route our customers manufacturers of active pharmaceutical ingredients (APIs) and fragrances gain two advantages: reduction of production costs and a more sustainable process. Development, production and distribution of in vitro-diagnostics for analytical purpose and the distribution of medical products. DIZG German Institute for Cell and Tissue Replacement engages in cell and tissue preservation as well as in cell and tissue replacement, and provides tissue preparations of human origin to clinics, teaching and research organisations. Further service is culturing of skin cells (keratinozytes) for serious burns and other skin defects not healing well or affecting large areas. DIZG supplies cell cultures to help avoid experimentation with animals e.g. in the cosmetics industry. Contract research and contract manufacturing using bacteria, yeasts and fungi. Innovative company engaged in development, production and marketing of specialized microcapsules for bio- and medical technology - Development and production of novel DNA-Purification-Kits with proprietary technology - Production and marketing of microcapsules (LUMiTainer), microbeads and cell based sedimentation standards for blood analysis (Sedi-Val ESR standards) - Encapsulation of cells - Contract analysis for characterization of microcapsules, porous membranes and hollow fibres. Handling with research and development of ecological products its process of development also its production and marketing - Production and refinement of plantingredients - Operate an analytical laboratory of renewable resources and chem. Analysis. Dr. Roelleke is specialized on the identification of microorganisms, particularly in the area of food safety. Furthermore, Dr. Roelleke is authorized expert on paternity tests for courts and the private sector. cellserve.de celltrend.de chemicell.com chipron.com chiracon.de cmz-assay.com codon.de congen.de cyano-biotech.com dendropharm.de dexlechem.com diaglobal.de dizg.de drgoetz.de lerche-biotec.com dr-otto-gmbh.de dr-roelleke.de 50

BioTOP-Report Addresses Biotech Companies Drug Response Dx GmbH E.R.D.E.-AAK-Diagnostik GmbH EMP Biotech GmbH Epigenomics AG Epinamics GmbH Epiontis GmbH Epo Experimentelle Pharmakologie & Onkologie GmbH Eternygen GmbH Eurovir Hygiene-Institut/Dr. Thraenhart EVESTRA GmbH F.A.T. Forschungsinstitut für Antioxidative Therapie GmbH Fermtec GmbH FILT Lungen- und Thoraxdiagnostik GmbH Formula GmbH G&Life SpA GA Generic Assays GmbH Gene Analysis Service GmbH GenExpress Gesellschaft für Proteindesign GmbH DRDx makes drug response predictable: Challenge and necessity of personalized medicine and individualized therapies demand for convincing and reliable companion diagnostics. The first field of activity of DRDx is Rheumatoid Arthritis (RA). The goal of our company is the technical and clinical validation of an IVD test kit for the reliable prediction of therapy response to TBAs ahead of treatment. E.R.D.E.-AAK-Diagnostik GmbH is a laboratory that offers antibody testing for commercial purposes. Production of fluorescent dyes and chemiluminescent reagents. Contract chemical synthesis of small molecules. Contract labeling and purification of proteins, antibodies and oligonucleotides. Production of size-exclusion gels, columns and filter plates. Production of high quality reagents for DNA synthesis. Development and commercialization of innovative molecular diagnostic test products based on DNA methylation for cancer screening and for cancer specialty applications. Epinamics GmbH, a newly established Berlin based pharmaceutical research and development dedicated company, is owner of a proprietary film forming formulation technology platform, the?invisible Patch? system. The system is offering a broad basis for the development of formulations for treatment of dermatological diseases as well as for the development of transdermal systems. Establishing methylation fingerprinting as Gold Standard for quality control in Regenerative Medicine and Immunomonitoring. The pharmaceutical and oncological testing of new drugs or treatment concepts for cancer is a specialized market segment. Using the equipment available, all experimental techniques can be carried out in first-rate quality. That means that EPO is an attractive partner for the drug development section of large pharmaceutical companies, for partners from the Biotech industry and for research institutions. Eternygen is a Berlin based start up founded in June 2012 focusing on research, development and marketing of innovative drugs using a network of renowned scientists and contract research organizations. The main focus of Eternygen s development and core competences of its founders are research and development of new drugs for dietary-related metabolic diseases with dramatically increasing prevalences in the last decades. Laboratory service for testing the efficiency of products against viruses (virucides) and of processes for inactivating or eliminating viruses (virus safety). EVESTRA is a newly founded biotech company focusing on developing female health products. The companies expertise resides with steroid chemistry and biology. EVES- TRA s product pipeline includes products for contraception, hormone replacement therapy, gynecological disorders and hormon dependent cancers. Measuring instruments and kits for evaluating the antioxidant properties and the degree of oxidative damage in biological substrates. Development of non-alcoholic beverages, beers and beer mix beverages, lactic acid fermentation, innovative foods and beverages and auxiliary substances for the food industry. Development of innovative, non-invasive diagnostic methods in the area of respiratory diseases and allergies. Galenical development of liquids and solid formulations Lyophilization Technolgy also apllicable for biochemical products Granulation, drying and coating using fluid bed drying-technology, tabletting Development and validation of analytical methods including UPLC Stability testing (ICH / GMP related to on going) Import of medicinal poducts from non-eu-countries, manufacturing, quality control (re-test) and release for market in accordance with 16 AMWHV for medicinal products and clinical supplies GMP-certificat / Manufacturing license in accordance with 13 AMG. G&life provides personalized strategies based on genetics. The life-science company is made up of a multi-disciplinary team combining expertise in genetics, nutrition, sport and engineering to develop products and services aimed at improving the quality of life. Development, manufacturing and distributing of in vitro-tests, focussing on autoimmune diseases, hereditary and infections diseases. Gene Analysis Service is specialized on genetic testing of a number of rare hereditary diseases and provides nucleic acid based molecular biological services like PCR and custom DNA sequencing for healthcare providers and research institutes worldwide. GenExpress is a flexible company providing services in molecular biology. For over a decade we have successfully worked for customers in clinical laboratories, research institutions and the industry. We offer cloning of PCR targets, preparation of synthetic genes, expression of proteins, evaluation of LightCycler assays, furthermore production of internal controls and standards for Real Time PCR systems, also cloning, expression and purification of proteins. drdx.de aak-diagnostik.de empbiotech.com epigenomics.com epinamics.com epiontis.com epo-berlin.com eternygen.com eurovir.de evestra.com antioxidant-research.eu fermtecgmbh.de filt.de formula-pharma.de glifecompany.com genericassays.com gene-analysis-service.de genexpress.de 51

BioTOP-Report Addresses Biotech Companies GILUPI GmbH GlucoMetrix PVS GmbH Glycon Biochemicals GmbH Glycotope GmbH GlycoUniverse GmbH GILUPI is a medical diagnostics company with an initial focus on the prenatal and cancer market. The company is developing an innovative new diagnostic product based on nanotechnology. Our goal is to catch specific cells, which can be found only in very low concentration in the blood. The first application for our new nanosensor device will be prenatal diagnoses of chromosomal aberration out of maternal blood. The second application will focus on the early diagnosis of cancer. The GlucoMetrix AG focuses on the early detection and management of diabetes mellitus-aftermath. At the foreground of research and development is the enhancing the quality of life of diabetics. In addition, the life science company develops some IT-based diagnostic procedures and medical devices as well as biopharmaceuticals and other highly effective products in order to raise the quality of life of diabetics sustainably. Production of carbohydrate components used for the synthesis of new pharmaceutical compounds or diagnostics. Glycotope is a leading company in glycomics and immunotherapeutics. It has developed novel therapeutic antibodies and unique platform technologies to optimize the glycosylation of new biological entities. Glycotope Biotechnology, with 25 years of experience in GMP-production, enables us to offer the entire process of biopharmaceutical development with a dedicated focus on our unrivalled expertise in protein glycosylation from the gene to production and fill & finish of clinical grade material. GlycoUniverse GmbH & Co KGaA is a technology spin-off of the Max Planck Institute of Colloids and Interfaces. Registered on 10th October 2013, the company deals with the automated development and synthetic production of complex sugars and is seeking customers and collaboration with leading scientific institutes in Europe and world-wide. gilupi.com glucometrix.de glycon.de glycotope.com glycouniverse.de Götz Protein Engineering Offering a wide range of protein technology up to the final purified protein. goetz-protein-engineering. de HealthTwiSt GmbH HF Biotec Berlin GmbH Hybrotec GmbH ICI GmbH Icon biotech IDrug GmbH Ifp Institut für Produktqualität GmbH IGV Institut für Getreideverarbeitung GmbH IKDT Institut Kardiale Diagnostik und Therapie GmbH HealthTwiSt is a service provider for Genetic Contract Research in the fields of Functional Genomics, Epigenetics, Proteomics or Functional Food / Nutriceuticals. In particular, HealthTwiSt is offering access to extensively characterized human subjects and samples as well as prospective studies in twins, together with know-how in the analysis of complex genetic traits. Furthermore, database development, data management and statistical analyses for clinical projects are provided. Development, selling and operating of digestion plants using liquid substrates of industrial and agricultural provenience, Development and operating of combined plants to upgrade biogas into bio methane useable in public gas grids with parallel production and selling of high quality PCC, Development of innovative biotechnological processes and plants. Hybrotec GmbH is specialized in the development of monoclonal antibodies and immunoassays (preferably homogenous assays) as customs service. Our main focus lies on antibodies binding low molecular weight substances (e.g. toxins, fluorophores, hormones) as well as antibodies against novel proteins. ICI immunochemical intelligence gmbh is dedicated to the development and production of innovative immunoassay components and kits for research use. Their goal is to provide individual solutions, exactly tailored to the client s needs and to create lasting relationships by providing outstanding services and high quality products to demanding clients. Icon biotech is an innovative biotechnology company, which uses the extraordinary characteristics of Ciliates for the development of bio-analytical and toxicological model systems. IDrug supports business strategies with innovative methodologies in analytical and biopharmaceutical chemistry Ifp Institut für Produktqualität is a laboratory and competence centre for state-of-the-art food, drinking water and pharmaceutical analysis. The accredited and GMP-certified company focuses on comprehensive services for the food and pharma industry. An additional core competence of ifp is the development and production of innovative diagnostics comprising the real-time PCR kits of the brand mericon (QIAGEN), vitamin tests in microtiter plate format, enzymatic microtiter plate kits for sugars/acids, and allergen tests in lateral flow and ELISA formats. The range of services offered by the Biotechnology Division of the private research IGV GmbH institute is based on 25 years of experience in R&amp,D for the cultivation of phototropic micro-organisms. Excellent, world-wide contacts to biomass producers, food producers, to the pharmaceutical and cosmetics and energy industry provide the fundament for innovative, market-oriented developments. In focus are development of photo bioreactor technology and active substances from algae. IKDT was founded in August 2002 in Berlin-Steglitz and is one of the leading laboratories on Viral Infections of Heart Muscle Tissue and Dilatated Cardiomyopathy (DCM) in Germany. IKDT lab is performing a comprehensive molecular diagnostic examination of endomyocardial biopsies as one of a limited number of specialized cardiological labs worldwide. Its service enables physicians firstly to start an efficient, pathophysiologically based causal therapy. healthtwist.de hf-biotec.com hybrotec.com ici-diagnostics.com icon-biotech.com idrug.de produktqualitaet.com igv-gmbh.de ikdt.de 52

BioTOP-Report Addresses Biotech Companies ILBC GmbH ImaGenes GmbH In.vent DIAGNOSTICA GmbH inbion GmbH Innovative Optische Meßtechnik GmbH Institut für Medizinische Molekulardiagnostik (IMMD) GmbH Institut für Molekular- und Systemmedizin I.M.S.M. GmbH InterMune GmbH InVivo Biotech Services GmbH InvivoContrast GmbH JPK Instruments AG JPT Peptide Technologies GmbH KNAUER - Wissenschaftliche Gerätebau Dr. Ing. Herbert Knauer GmbH L.U.M. Gesellschaft für Labor-, Umweltdiagnostik & Medizintechnik mbh labfolder GmbH Research, consulting, production, trade & services in the areas biology, molecular biology and protein chemistry - Expression and production of antimicrobial peptides. RZPD spin-off, today part of Source BioScience plc, a premier service center for genome research and healthcare in Europe, provides one of the largest clone collections in the world via its clone search engine GenomeCube. Certified Service Provider for illumina Next Generation Sequencing services and comprehensive microarray application on Affymetrix, Agilent, and NimbleGen platforms. ISO 9001:2008 certified. in.vent DIAGNOSTICA GMBH is a biomedical company. We are focused on the project-oriented provision, processing and distribution of biological raw material for development and production of diagnostics and control material. We are your reliable partner for the customised development of assays for medical in vitro-diagnostics. inbion GmbH provides services to support research in the interface between university, students and industry. For companies, we provide the benefit of outsourcing projects quickly and cost-efficiently to competent teams. Cooperation with research groups in the university is also facilitated, so that targeted knowledge transfer can take place here. Fluorescence Assay Solutions and Instrumentation (Microplate Readers). Gene tests for prenatal, predictive and tumor -diagnostics. Scientific-practical works in the area of System medicine with the purpose of the patenting of new treatment methods, e.g. to the treatment of diabetes. International cooperation in this area. InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and fibrotic diseases. In pulmonology, we are focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease. As a contract manufacturing company (CMO) Invivo offers a wide range of services: the development and production of monoclonal antibodies and recombinant proteins for diagnostic and pre-clinical use (endotoxin-free antibodies and compliant documentation), cell line development and transient transfection. We are an ISO9001:2008 certified company. InvivoContrast provides globally high quality MRI (Magnetic Resonance Imaging) contrast agents and professional support for preclinical imaging in academic and commercial institutions. JPK Instruments AG is a world-leading manufacturer of nanoanalytic instruments - particularly atomic force microscope (AFM) systems and optical tweezers - for a broad range of applications reaching from soft matter physics to nano-optics, from surface chemistry to cell and molecular biology. From its earliest days applying atomic force microscope (AFM) technology, JPK has recognized the opportunities provided by nanotechnology for transforming life sciences and soft matter research. JPT is an ISO 9001:2008 certified provider of innovative peptide products and services and a partner for research projects focusing on the development of novel immune therapeutics & diagnostics, profiling of various enzyme classes and proteomics. JPT has developed a portfolio of proprietary technologies and a series of unique products which support a worldwide customer base. Since 2011 all catalog products such as peptide microarrays & peptide pools are avalaible through an online shop. KNAUER UHPLC and HPLC systems as well as columns are used in research and development, quality control and production plant laboratories around the world. Customers are typically governmental and industrial organizations as well as universities. Fields of application are wide-ranging and include pharmaceutical and medical research, analysis of foodstuffs and cosmetics, as well as environmental analysis. With our biochromatography solutions we focus on high resolution separations. Analysis, diagnosis and sensor technology as well as stability, rheology and segregation behavior of dispersions. labfolder is a digital notebook and collaboration platform for laboratory research. As a viable alternative to traditional paper-based laboratory notebooks, labfolder allows scientists to document and organize their research, plan their experiments and collaborate with others digitally. The software provides an intuitive user interface and is compliant with the rules of Good Scientific Practice (GxP), including full audit trail and digital signatures for maximum intellectual property protection. labfolder is also available on all mobile devices operating under Android and ios, allowing scientists to access and manage their data from everywhere. labfolder is free for individual scientists and small groups and offers advanced functions for large research groups and enterprises for a monthly fee. mobiclup.de imagenes-bio.de inventdiagnostica.de inbion.de iom-berlin.de immd.de intermune.de invivo.de invivocontrast.com jpk.com jpt.com knauer.net lum-gmbh.de labfolder.com 53

BioTOP-Report Addresses Biotech Companies Labor Berlin Charité Vivantes Services GmbHLabor Berlin Charité Vivantes GmbH LGC Genomics GmbH Labor Berlin Services is the service subsidiary of Europe s largest hospital laboratory for clinical pathology and offers complete solutions for any kind of testing for the ivd industry, CROs, the pharmaceutical industry, life science companies and research facilities, while Labor Berlin is the exclusive laboratory partner of Charité - Universitätsmedizin Berlin and the Vivantes Network for Health. Labor Berlin and Labor Berlin Services both perform over 35 million analyses in clinical pathology per year and provide the diagnostic services for approximately 400.000 in-house patients a day and some one million out-patients per year. LGC Genomics is the division of LGC with specific expertise in high quality, cutting-edge genomic and related services and products. LGC Genomics delivers:- Next generation sequencing services- DNA sequencing- Genomics services- Nucleic acid extraction services- DNA extraction products. LGC is an international science-based company and market leader in analytical, forensic and diagnostic services and reference standards (lgc.co.uk). laborberlin.com lgcgenomics.com LGC GmbH Production of calibration substances for purity testing of drugs. mikromol.de Life Glimmer Limetec Biotechnologies GmbH Lipidomix GmbH MagForce AG Marinpharm GmbH MedInnovation GmbH Medipan GmbH MerLion Pharmaceuticals GmbH Merz Pharmaceuticals GmbH / Standort Potsdam Metabolomic Discoveries GmbH Metanomics GmbH Metanomics Health GmbH MetrioPharm AG Mfd Diagnostics GmbH Life Glimmer is a customer-oriented consulting and contract research company with the goal of providing the biotechnological, biomedical and environmental research communities an efficient way to outsource scientific modeling and computing needs. The core competence lies in the development of high-speed and high-quality proof systems for the detection of pathogens, as well as in the allelic discrimination of hereditary diseases. All products are marked with the CE-Certificate. The second area of expertise is the creation of communication networks which connect out-patient and hospital patient treatments, intensify data exchange and provide information to all health institutions, thus establishing partner relationships between them. LC/MS/MS based high trouput analytic of lipid mediators and metabolites. Analytical method development, analytical support for LC/MS/MS in life science, food safety, forensic science. MagForce AG is a leading medical technology company focusing on nanomedicine in oncology. The company s proprietary procedure, NanoTherm therapy, enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of magnetic nanoparticles. NanoTherm, NanoPlan, and NanoActivator are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. Development and marketing of genetically altered cell lines on the basis of new fluorescence markers. Generation of stably transfected fluorescent cell lines. MedInnovation GmbH has developed a new method and a special ESR-analyser, which for the first time allows a simple routine laboratory test for evaluation of functional characteristics of plasma proteins and further opens a reliable possibility for cancer diagnostic, named MMS-technology (mobility of molecular structure). Development, manufacturing and international distribution of radioactive (125J-IRMA) and non-radioactive (Elisa) in vitro-diagnostic tests, covering the field of Autoimmunity, mainly in Thyroid and Diabetes Typ 1 and automated interpretation of cell-based immunofluorescence tests by the AKLIDES system. The business purpose of the Company is the research, production, optimization and the development by way of pre-clinical as well as clinical trials of new molecules for the treatment of infectious diseases. Merz is one of the leading research-based health care companies. Merz Pharmaceuticals has achieved a leading position in Alzheimer s research with the world s first drug for the treatment of moderate to severe Alzheimer s disease. With high quality products from tetesept and Merz Spezial, Merz is making a key contribution to health and wellbeing. Metabolomic Discoveries is an analytical service and research company. We provide mass spectrometry based metabolite profiling and fingerprinting of biological material, as well as single compound measurements. Metabolite Profiling for identification of gene function relationship in plants, metabolite biomarkers and metabolic networks. Identification of metabolic biomarkers for pharmacology, toxicology, diagnostic and nutrition. MetrioPharm AG develops innovative therapies for infectious diseases on the basis of new and innovative medicines. The mfd Diagnostics GmbH (BT Luckenwalde) is a life science research and development company for diagnostic and therapeutic application of innovative laser technologies. The main advantages of the developed technologies are the non-/minimally-invasive measurement methods, the non-artificial approach and the possibility of real-time measurement. Therefore, those are promising tools for the diagnosis and therapy monitoring in the neurological practice and in the perinatal surveillance. lifeglimmer.com limetec-biotechnologies.de lipidomix.de magforce.com marinpharm.com medinnovation.de medipan.de merlionpharma.com merz.de metabolomicdiscoveries. com metanomics.de metanomics-health.de metriopharm.com mfd-diagnostics.com 54

BioTOP-Report Addresses Biotech Companies MicroDiscovery GmbH Microparticles GmbH Minerva Analytix GmbH Minerva Biolabs GmbH mivenion GmbH MLB Mikrobiologisches Labor GmbH Molnar-Institut für angewandte Chromatographie MOLOGEN AG molox GmbH MRI.TOOLS GmbH Myelo Therapeutics Nano Access Technologies Ltd. Nanolytics Gesellschaft für Kolloidanalytik mbh Nanopartica GmbH MicroDiscovery GmbH is a leading provider of high quality software for biomolecular research, innovative diagnostics and personalised medicine. The company is ISO 9001 certified and has a strong track record in creating software systems in accordance with relevant regulatory directives for the life science and IVD industry. Customised services ranging from biostatistical data analysis to bioinformatical design and support of complex research projects complete the product line of MicroDiscovery. Development, manufacture, surface modification and characterization of mono-disperse polymer particles in the nano- and micrometer range. In addition to classic polystyrol and polyacrylate-based polymer particles, microparticles GmbH has launched new melamine resin particles on the market with exceptional chemical and physical qualities. The main areas of application are in particle measurement technology, medicine, biochemistry and microelectronics etc. Minerva Analytix GmbH is a leading analytical service lab for the control of microbial contamination. Our core competence lies in the control of mycoplasma, bacteria and viruses in cell cultures and biopharmaceuticals Minerva Biolabs develops and produces IVD kits for diagnosing pathogens and for contamination control, especially mycoplasma in cell cultures and biopharmaceutical products. Minerva Biolabs is also active in ensuring water quality with sensitive processes for detecting legionella. Our distributors ensure that our products are available worldwide, quickly and at a good price. mivenion is a life-science company founded in Berlin aiming on the development and commercialization of diagnostic and therapeutic products. The company is built on two innovative technologies: the fluorescence camera system Xiralite for diagnostic imaging of early rheumatoid arthritis and a proprietary bioactive polymer drug development platform. Xiralite is mivenion s first product on the market. Accredited test laboratory for drinking water, clean rooms, sterility, bioburdens, D-PL- 13398-01-00, EN 17025. Accreditation according to VDI 6022. Molnar-Institute, established in 1981, offers you a complete scientific and technical service for all problems concerning Quality by Design (QbD) for HPLC-methods. We develop for you the Design Space for your HPLC-separation and establish Critcal Quality Attributes (CQA s). We offer detailed DryLab-courses and show you, how to develop robust methods in the Design Space and how to save time. We supply and implement the DryLab-software and train your coworkers. We assist you in automated method development processes and support you in the selection of proper instruments, their installation and use. MOLOGEN AG is a biopharmaceutical company based in Berlin and specializes in the development of novel DNA-based medicines against cancer and vaccines against infectious diseases. The proprietary platform technologies MIDGE and dslim build the foundation for all business activities. The company was founded 1998 and was one of the first biotechnology companies to go public. molox GmbH is a company focusing on custom protein production in bacterial and insect cell expression systems and subsequent protein purification to ultra-high purity. On customer demand a team of experts can perform protein crystallization experiments and determine the 3D structure of target proteins by X-ray crystallography. MRI.TOOLS s main focus is the development, sales and services of innovative hardware and novel technology for magnetic resonance imaging (MRI), computed tomography (CT) and positron emission tomography (PET). Our product portfolio encompasses enabling radiofrequency (RF) coils tailored for a broad range of applications, devices designed for reliable cardiac gating of imaging plus accessories that will make your daily life more comfortable. MRI.TOOLS is also very proud to offer consulting services such as validation and certification of medical devices. Myelo Therapeutics GmbH develops innovative treatments in areas of high unmet medical needs. The company addresses the combined access to key technologies such as life science and nanotechnology. As a first product, a low cost AFM for operation with so-called active cantilevers has been developed. Besides this, functionalized cantilevers for future biosensors are another focus of the company. We are a contract laboratory specializing in the physico-chemical characterization of pharmaceutical proteins, biopolymers, nanoparticles and colloidal systems. Our core-competences are Analytical Ultracentrifugation, in combination with Static and Dynamic Light Scattering as well as spectroscopic (CD, fluorescence) and thermodynamic techniques (ITC, DSC). Nanopartica GmbH optimizes existing products of other companies, but are also developing new products and materials. In particular, companies in surface-, bio-, and medical-technology can benefit from nanopartica. By means of functionalized polymers, we can encapsulate guest molecules (drugs, dyes, vitamins), particles (gold, silver, platinum), or ions. This will indirectly change the guests properties and expands its scope. microdiscovery.de microparticles.de minerva-analytix.com minerva-biolabs.com mivenion.com mikroberlin.de molnar-institute.com mologen.com molox.de mritools.de myelotherapeutics.com nano-access.com nanolytics.de nanopartica.com 55

BioTOP-Report Addresses Biotech Companies nanopet Pharma GmbH NovaBiotec Dr. Fechter GmbH NOXXON Pharma AG OakLabs GmbH OctreoPharm Sciences GmbH Omeicos Therapeutics GmbH OpTricon Entwicklungsgesellschaft für optische Technologien mbh ORGANOBALANCE GmbH ORGANOBALANCE Medical AG ovalehn GmbH Pentracor GmbH Peptides&elephants GmbH PharmaSol GmbH PlasmaChem GmbH As a technology and service provider to the biopharmaceutical industry nanopet focuses on the R&D, production as well as marketing of innovative drug substances for diagnostic imaging based on novel nanoparticular materials. nanopet offers consulting and contract research services, preclinical contrast agents (MRT, CT, US, NIR, PET) as catalog items and pursues the preclinical development of its patented core technology of inorganic nanoparticle PET tracers. Microbiological and chemical investigations, in particular of soil, water and air samples, planning / inspection of sanitation, in particular analytics and sanitation support for mould and dry rot, incl. education in this field. Delivery of production auxilliaries and support for biogas plants with biological treatment processes incl. application, insulation and preservation of enzymes. Research, development and marketing of test kits for breweries and malthouses. NOXXON Pharma is a biopharmaceutical company pioneering the development of a new class of proprietary therapeutics called Spiegelmers. Spiegelmers are the chemically synthesized, non-immunogenic alternative to antibodies. NOXXON has a diversified portfolio of clinical stage Spiegelmer therapeutics: Spiegelmer NOX-E36, Spiegelmer NOX-A12, Spiegelmer NOX-H94. The Spiegelmer platform provides the Company with powerful and unique discovery capabilities, which have generated a number of additional leads under preclinical investigation. Located in Berlin, Germany, NOXXON is a well financed mature biotech company with a strong syndicate of international investors, approx. 60 employees and a highly experienced management team. OakLabs provides the most flexible products and services for large scale custom SNP genotyping on the market. OakLabs offers several formats for analysing a variable number of SNPs in any sequenced organism. OctreoPharm Sciences GmbH is a clinical development company focusing on diagnostic radiopharmaceuticals. OMEICOS Therapeutics is developing a novel, first-in-class, small molecule utilizing a new Mode of Action for the treatment and prevention of atrial fibrillation. OMEICOS' novel therapeutic strategy is based upon the discovery of natural metabolites of omega-3 fatty acids that mediate a strong anti-arrhythmic effect. In contrast to all other anti-arrhythmic drugs, OMEICOS' substances activate an endogenous cardio-protective signaling pathway that not only stabilizes the heart rhythm but shall provide curative effects to the diseased organ by preventing its electrical and structural remodeling. OpTricon develops and produces mobile readers for quantitative analyzes of Immunoassays for Point-of-Care-diagnostics, especially Lateral Flow Assays (LFA). Additional business segments are components and Systems for signal transmission and sensors for lbioanalytics. optricon develops the devices in partnership with the customers and works as OEM-suppliers and is certified by TÜV Rheinland according EN ISO 13485:2003+AC: 2007 and EN ISO 9001:2008. ORGANOBALANCE is a company specializing in microbial strain development and screening. As a R&D contractor ORGANOBALANCE develops new biological products in the areas of nutrition, personal care and health care. The company draws on its own collection of microbial strains suitable for food applications and its OASSYS bioassay systems. In the field of metabolic engineering ORGANOBALANCE exploits Saccharomyces cerevisiae yeast for synthesis of substances for the industrial and pharmaceutical industry. ORGANOBALANCE Medical AG funds and promotes the research and development of novel therapies based on specific probiotic cultures, aiming to develop active substances and mechanisms for innovative medicinal products and medical devices, as well as offer new therapeutic concepts for hitherto inadequately treatable indications. Production and application of specific recipes -containing IgY for diagnostics and oral, passive immune therapy. In the case of cardiac infarction, C-reactive protein (CRP) results in an increase of the primary damage. Based on a new prototype, the company Pentracor GmbH aims to develop an adsorber for therapeutic reduction of CRP, lead it to approval, establish its certified production and market the product after clinical validation. Custom synthesis of peptides and peptide libraries Development parallel Synthesis technologies Distributor of Peptide Synthesis Automation. Modification of ingredients or introduction of new metabolic pathways in plants with gene-technology methods. PlasmaChem GmbH is an innovative R&D and manufacturing company specializing in nanomaterials, plasma- and ultra-thin film technologies. The company manufactures nano-coated medical implants (stents), nanomaterials, additives for metal plating (applied e.g. by Siemens AG), new additives to engine oils on the base of nanodiamonds and other industrial nanoproducts. nanopet-pharma.com novabiotec.de noxxon.com oak-labs.com octreopharmsciences.com omeicos.com optricon.de organobalance.com organobalancemedical.com ovalehn.de pentracor.com peptides.de pharmasol-berlin.de plasmachem.com 56

BioTOP-Report Addresses Biotech Companies PolyAn, Gesellschaft zur Herstellung von Polymeren für spezielle Anwendungen und Analytik mbh Preclinics Gesellschaft für präklinische Forschung mbh Predemtec GmbH ProBioData GmbH ProBioGen AG ProteaImmun GmbH PROTEKUM - Umweltinstitut GmbH, Oranienburg Proteome Factory AG Provitro GmbH Rapidozym Gesellschaft für Laborhandel und DNA Diagnostika mbh RENESA UG (haftungsbeschränkt) RiNA GmbH RIPAC-LABOR GmbH Roboklon GmbH PolyAn is specialised in Molecular Surface Engineering (MSE). Using our surface modification expertise PolyAn optimises the performance of analytical systems by improving the signal-to-noise ratio as well as the reproducibility of consumables for multiplex diagnostics, LifeScience research and screening applications. PolyAn?s product portfolio includes functionalised microarray slides, microparticles for multiplex bead arrays and functionalised membranes for medical diagnostic applications. Preclinics is a commercial cooperation partner for preclinical research and development. As a competent, creative and experienced partner preclinics investigates pharmaceutical substances, therapeutic methods and proceedings as well as medical products during the preclinical phase. Additional we provide custom antibody production in llama, goat, sheep, rabbit and other species. Predemtec GmbH is a company focused on the research, development and manufacture of innovative diagnostic tests for use in the detection of dementia-related risk factors. The goal has been to make the early and reliable diagnosis of various dementia-related illnesses a reality through the use of our innovative diagnostics tests. BioProcessDB is a database solution for bioprocess R&D. It's designed to become the linking tool in your information process and to integrate the data i. e. from the SCADA system, the sample data management and the strain management. ProBioGen is a Contract Development and Manufacturing Organization (CDMO) and Technology Provider, with extensive expertise in cell line engineering, process development (upstream- and downstream process) and GMP manufacturing of biopharmaceuticals. Offering state-of-the-art contract development and manufacturing services as well as access to proprietary cell lines (AGE1.cell lines ) for the manufacturing of biopharmaceuticals and vaccines. The company possesses the manufacturing authorization from the competent authority and meets the quality standards required by the EMA and the FDA guidelines. ProteaImmun is a specialized proteomic company providing purified human proteins, antibodies and ELISAs. Our proteins are designed for structural and functional studies of proteases screening and evaluation of protease inhibitors and modulators. Furthermore we develop highly sensitive ELISA kits and antibodies. Our Focus: MMPs, ADAMTs, HtrAs. ProteaImmun produces a unique range of recombinant proteases for medical and pharmaceutical research. The main focus is on human Matrix Metalloproteases (MMPs), ADAMTS and HtrA proteins which play an important role in neurodegenerative disease, ancer and arthritis. Customer Service: ProteaImmun provides activity analysis by zymography adapted for MMPs. We plan to eliminated fluid und solid waste products in a manner which is compatible with environment protection. Our methodology is largely based on painstaking analysis. We use modern equipment and scientific methods. Protekum offers high-quality products and services in environmental analysis redevelopment. Biomarker & target discovery, validation, analysis of food and ingredients, absolute quantification of proteins and peptides, sequencing and characterization of proteins and antibodies (CDR), 2DE and LC-MS based proteomics studies, pharmacokinetics, pharmaco, immuno and membrane proteomics, protein identification, characterization of proteins and peptides (PTMs, e.g. phosphorylation, glycosilation), quality control, mass determination, N-terminal amino acid sequencing, silver staining kit etc. Provitro combines more than ten years of experiences in commercialisation of cell culture technologies, Tissue Microarrays and immunohistochemical analyses with the scientific expertise of the Pathological Institute of the Charité, Berlin. Based on a quality management system according to ISO 9001:2008, we provide our customers not only with high-quality products, CE marked in vitro-diagnostics and state-of-the-art services but also with individual solutions for their specific requests. Expertise of cell biologists cell manufacturing and clean room technology specialists. Focuses on clinical stem cell product development portfolio are stroke, myocardial infarction and plastic surgery. Manufacturing and distribution of rapid tests, mainly for medical purposes (Point of Care Testing). RiNA has developed systems for cell-free protein biosynthesis based on pro- and eukaryotic cell lysates. A synthesis service is realised in RiNA s own laboratories and complements the EasyXpress Kits (Qiagen). The purchase of Roche s RTS-products enables RiNA now to be a key player in the field of cellfree biosynthesis with a large variety of products. Another research focus is the development of aptamers (DNA and RNA) for biosensors. RIPAC-LABOR offers high-quality diagnoses of bacterial infections, particularly in poultry, pigs and cattle, but also in other farm and domestic animals. The company uses pathogen differentiation to provide quick and effective methods for fighting pathogens. It performs resistance tests and epidemiological analyses and also focuses on producing herd-specific vaccines. Distribution, Marketing and Development of Products for Molecular Biological Research and Genetic Engineering. poly-an.de preclinics.com predemtecdx.com probiodata.de probiogen.de proteaimmun.net protekum.de proteomefactory.com provitro.de rapidozym.de renesa.de rina-gmbh.eu ripac-labor.de roboklon.de 57

BioTOP-Report Addresses Biotech Companies ROVALAB GmbH Royal Biotech GmbH Scienion AG Sepiatec GmbH Seramun Diagnostica GmbH SGS INSTITUT FRESENIUS Berlin GmbH & Co. KG SIFIN Institut für Immunpräparate und Nährmedien GmbH Berlin Signature Diagnostics AG Silence Therapeutics AG SINA Science Services GmbH SLM- Speziallabor für angewandte Mikrobiologie GmbH Sopat GmbH STRATEC Molecular GmbH Strix Diagnostics GmbH Surflay Nanotec GmbH Our Master Mixes for QPCR, Standard-, Hot Start- and High Fidelity PCR as well as our high quality critical raw materials and reagents such as DNA Polymerases and dntps are designed to help you successfully and rapidly solve your scientific and manufacturing tasks. Royal focuses on developing, manufacturing and marketing innovative kits, portable or micro-structured systems, and the next generation of diagnostic chips for near real-time environmental, food safety, disease and laboratory diagnostics. Scienion is a life science company in the markets of dispensing systems and microarray technologies. The product portfolio comprises hardware, consumables and services. Scienion s leading product is the sciflexarrayer dispensing system, available in a product line of six size versions. The dispenser allows the aspiration of ultra low liquid volumes from different reservoirs and non-contact micro drop delivery in the picoliter to microliter range onto a variety of carriers. Production, development and sales of automated HPLC machines for high-throughput purification and fractioning of complex substance compounds. Seramun offers peptide synthesis, purification and conjugation of proteins, production of antibodies, customer research, in vitro-diagnostics. We focus on the development and production of enzyme immunoassays for diagnosis of viral and bacterial infections and autoimmune diseases of the gastrointestinal tract, the development of multi-parameter assays as microtitre plate assays and as membrane immunoassays, as well as development of ready-to-use substrate solutions and for protein stabilizers. Analytical laboratory services and consulting for development, production and quality control of drugs. Development, production and purification of monoclonal antibodies for use in diagnostics. Development and production of blood grouping reagents, Serafol bedside cards and test reagents for serotyping of Salmonellae, Shigellae, E. coli and Yersiniae. Development and production of culture media for microbiological diagnosis. Signature Diagnostics is dedicated to the discovery, validation and commercial development of novel diagnostic products that predict outcome and drug response in patients with colorectal cancer (CRC), non-small cell lung cancer (NSCLC) and ovarian cancer. Signature believes that patient selection and stratification based on molecular gene signatures will soon become an important component of routine cancer treatment. Silence Therapeutics AG is a leading RNAi therapeutics development company and offers a novel, proprietary sirna technology (AtuRNAi) and proprietary systemic delivery systems for sirna (AtuPLEX, DACC and DBTC). SILENCE pipeline consists of both partnered and internal programs of which 3 clinical phase II and 1 clinical phase I programs are partnered with Pfizer/Quark (2 ophthalmic indications) and Novartis/ Quark (2 kidney indications). Silence?s internal lead compound Atu027 is currently in a Phase I clinical study for the treatment of solid tumours. SINA is a modern company providing elaborate services in molecular biology and protein biochemistry. Together with our industrial partners and customers from research institutions we develop complex cloning and mutagenesis strategies including high-throughput applications. We offer cloning of genes, expression and purification of proteins, DNA and RNA isolation from numerous biological materials and the production of competent cells with high transformation efficiency. Microbiological quality control for medical devices, pharmaceuticals, cosmetics, drinking water, foodstuff, monitoring in clean rooms. SOPAT is specialized in the analysis of particulate systems. The company develops and markets an innovative particle measurement technology for real-time analysis of multiphase systems. Particles, such as droplets, grains, cells or bubbles, are measured with high precision in running processes. STRATEC Molecular GmbH is a globally active provider of innovative system solutions for nucleic acid sample collection, stabilization, and both manual and automated purification from any sample type. Since 1992 the company is internationally respected for its outstanding and high performance technology platforms and offers a broad spectrum of superior products for molecular diagnostics, drug discovery and Life Science research. Strix Diagnostics is a medical diagnostics company specializing in customized development of certified analytical systems for multiparameter in vitro-diagnostics. Surflay Nanotec GmbH, a spin-off company from Capsulution NanoScience AG, is specialized on coating colloidal and planar materials with functional films. Key technology is the patented LbL-Technology with polymers. Applications are in the fields of separation materials, pigment encapsulation, bio-sensing and diagnostic particles. In addition to customer tailored projects Surflay offers an unique range of products of tunable multifunctional nano-or microparticles and dye-labeled polymers. rovalab.com royalbiotech.com scienion.de sepiatec.com seramun.com institut-fresenius.de sifin.de signature-diagnostics.de silence-therapeutics.com sina-science-services.de speziallabor.com sopat.de invitek.de strix-diagnostics.de surflay.com 58

BioTOP-Report Addresses Biotech Companies t-cell Europe GmbH Thanares GmbH t-cell Europe GmbH, a spin-off of the Berlin Brandenburg Center for Regenerative Medicines (BCRT), is aiming to become the world s technology leader in the application of T-cell-based therapies used in transplantation medicine. Over the next few years, with its three proprietary platform technologies, the company will develop and clinically validate novel T-cell-based products and corresponding diagnostics to regulate the immune system and treat viral infections. The company s lead reference product will be a first-in-class Treg cell product/therapy for kidney transplantation that suppresses organ rejection in recipients Development, use and marketing of analytical process for diagnostic and therapeutic purposes. Future business activities: detection process for bioactive substances in bodily fluids, isolation, characterization and investigation of bioactive compounds from plants, in particular insoluble proteins or low concentrations of proteins, development of low cost genetic systems for over-expression and/or production of such proteins. t-cell.de thanares.com TheraKine BioDelivery GmbH Development of antibody drug delivery systems and related tasks. therakine.com Thermo Fisher Scientific B R A H M S GmbH TIB MOLBIOL Syntheselabor GmbH TissUse GmbH TransTissue Technologies GmbH UGA Biopharma GmbH Umwelttechnik-Berlin UG Zellwerk GmbH Zentrum für molekulare Onkologie GmbH Zytomed Systems GmbH Thermo Scientific Biomarkers (B R A H M S GmbH) explores, develops and produces new diagnostic test procedures to improve the diagnosis, and thereby the treatment, of life-threatening illnesses. This takes place with over 470 employees, in the disease areas infectiology, cardiology and pneumology as well as thyroid, autoimmunity and cardiology on the basis of our own patented biomarkers. Since October 2009 B R A H M S GmbH is part of Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science. In 1990, TIB MOLBIOL became the first German manufacturer of oligonucleotides. In addition to designing and synthesizing primers and probes for Real-Time PCR assays, we develop and produce LightMix Kits for Roche Diagnostics LightCycler Instruments, covering applications in Clinical Chemistry, Pharmacogenetics, Pathogen Detection, as well as Cancer Research. TIB MOLBIOL is ISO 13485 and ISO 9001 certified. TissUse is a vibrant growth company providing high-value services in the area of tissue culture analysis of drug candidates, cosmetics, chemicals and consumer products. TransTissue has been a subsidiary of BioTissue Technologies, Freiburg since September 2001. With more than 15 years of experience in regenerative medicine, the scientists of TransTissue Technologies have developed second-generation autologous tissue replacements, e.g. cartilage and bone grafts. We are mainly concerned with inventions and the development of tissue engineering products for regenerative medicine. We offer a broad panel of services in the field of regenerative medicine. UGA Biopharma a private Research and Development company, focuses on Research, Development and Commercialization of Biopharmaceutical products under contract with other Biopharmaceutical companies. UGA Biopharma conducts power of biosciences to develop high-tech, last generation of biomedicine, diagnostic kits, molecular biology items and also offers world class services in biotechnology area. Feasibility studies, development, planning, construction and operation of biotechnological plants for groundwater, process water and waste water purification. Accredited microbiological laboratory for the investigation of drinking water, groundwater, bath water, soils, food, anti-microbial active ingredients and sterility according to Ph.Eur, approved in accordance with BiostoffV and the German infection protection act (Infektionsschutzgesetz). Zellwerk produces the proprietary Z RP cell cultivation system, comprising rotating bed bioreactor, GMP Breeder, Control Unit, software. Bioreactors with 50-5000 ml volume, 0,2-2 m² seeding surface, different cell carriers, can be delivered. In this culturing system cells grow tissue-like, being embedded in self-generated extra-cellular matrix. The technology opens unique opportunities for the GMP-compliant expansion of stem cells and primary cells, manufacturing of cell-seeded implants as well as production of recombinant proteins. In addition, we have recently developed a new bioreactor for expansion of immune cells for cell therapy of leukemia and several types of cancer. Innovative methods for diagnostic and therapy of tumor diseases - Molecular genetics (K-RAS, PCA3, Septin9,...) - Chemoresistance assay for prediction of chemotherapy - Pathology Development of new biomarkers and analytical services for studies. Zytomed Systems focus is the development, production and distribution of antibodies and detection systems for immunohistochemical cancer diagnostics as well as reagents and kits for in-situ hybridisation. thermoscientific.com/ brahms tib-molbiol.com tissuse.com transtissue.com ugabiopharma.com bartetzko.com zellwerk.biz molekulare-onkologie.eu zytomed-systems.de 59

BioTOP is a joint initiative of the state of Berlin and the state of Brandenburg under the umbrella of the Berlin Partner für Wirtschaft und Technologie GmbH and takes part in the Cluster Management HealthCapital. BioTOP is funded by the federal state of Berlin, the federal state of Brandenburg and the Investitionsbank Berlin, co-funded by the European Union (European Fund for Regional Development). Investing in your Future